Giuseppe Basso

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3657331/publications.pdf

Version: 2024-02-01

654	35,346	4146	5679
papers	citations	87 h-index	162 g-index

659	659	659	37276
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature, 2012, 481, 157-163.	27.8	1,430
2	The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells. Cell, 2011, 147, 759-772.	28.9	1,115
3	Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet, The, 1998, 352, 1731-1738.	13.7	876
4	YAP/TAZ Incorporation in the Î²-Catenin Destruction Complex Orchestrates the Wnt Response. Cell, 2014, 158, 157-170.	28.9	873
5	Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncology, The, 2009, 10, 147-156.	10.7	850
6	Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nature Medicine, 2007, 13, 1203-1210.	30.7	804
7	Tumor-Induced Tolerance and Immune Suppression Depend on the C/EBPÎ² Transcription Factor. Immunity, 2010, 32, 790-802.	14.3	782
8	Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. Journal of Clinical Investigation, 2006, 116, 2777-2790.	8.2	723
9	Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood, 2010, 115, 3206-3214.	1.4	685
10	Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Subclassification of Leukemia: Report From the International Microarray Innovations in Leukemia Study Group. Journal of Clinical Oncology, 2010, 28, 2529-2537.	1.6	567
11	Rearrangement of CRLF2 in B-progenitorâ€“ and Down syndromeâ€“associated acute lymphoblastic leukemia. Nature Genetics, 2009, 41, 1243-1246.	21.4	559
12	Hepatic Stem-like Phenotype and Interplay of Wnt/Î²-Catenin and Myc Signaling in Aggressive Childhood Liver Cancer. Cancer Cell, 2008, 14, 471-484.	16.8	443
13	The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. Journal of Experimental Medicine, 2007, 204, 1825-1835.	8.5	427
14	Role of TAZ as Mediator of Wnt Signaling. Cell, 2012, 151, 1443-1456.	28.9	419
15	Î³-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nature Medicine, 2009, 15, 50-58.	30.7	417
16	Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood, 2011, 118, 2077-2084.	1.4	370
17	Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia, 2008, 22, 771-782.	7.2	339
18	A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood, 2011, 118, 2254-2265.	1.4	328

#	Article	IF	Citations
19	Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet, The, 2008, 372, 1484-1492.	13.7	318
20	Gain-of-function mutations in interleukin-7 receptor-Î± (IL7R) in childhood acute lymphoblastic leukemias. Journal of Experimental Medicine, 2011, 208, 901-908.	8.5	307
21	Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nature Medicine, 2013, 19, 368-371.	30.7	304
22	Incidence and Clinical Relevance of TEL/AML1 Fusion Genes in Children With Acute Lymphoblastic Leukemia Enrolled in the German and Italian Multicenter Therapy Trials. Blood, 1997, 90, 571-577.	1.4	268
23	Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. Blood, 2004, 104, 307-313.	1.4	265
24	Intratumoral Hypoxic Gradient Drives Stem Cells Distribution and MGMT Expression in Glioblastoma. Stem Cells, 2010, 28, 851-862.	3.2	262
25	Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood, 2007, 110, 1112-1115.	1.4	250
26	Risk of Relapse of Childhood Acute Lymphoblastic Leukemia Is Predicted By Flow Cytometric Measurement of Residual Disease on Day 15 Bone Marrow. Journal of Clinical Oncology, 2009, 27, 5168-5174.	1.6	247
27	The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature, 2018, 562, 373-379.	27.8	236
28	Direct Reversal of Glucocorticoid Resistance by AKT Inhibition in Acute Lymphoblastic Leukemia. Cancer Cell, 2013, 24, 766-776.	16.8	220
29	SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors. Nature, 2012, 487, 380-384.	27.8	213
30	Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. Blood, 2016, 127, 2101-2112.	1.4	208
31	Induction of Expandable Tissue-Specific Stem/Progenitor Cells through Transient Expression of YAP/TAZ. Cell Stem Cell, 2016, 19, 725-737.	11.1	204
32	Modulation of microRNA expression in human T-cell development: targeting of NOTCH3 by miR-150. Blood, 2011, 117, 7053-7062.	1.4	199
33	GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood, 2005, 106, 447-453.	1.4	196
34	IKZF1^{plus} Defines a New Minimal Residual Diseaseâ€“Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2018, 36, 1240-1249.	1.6	194
35	Genomics and drug profiling of fatal TCF3-HLFâ^positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nature Genetics, 2015, 47, 1020-1029.	21.4	190
36	Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood, 2014, 123, 70-77.	1.4	189

#	Article	IF	Citations
37	Immunophenotype of adult and childhood acute promyelocytic leukaemia: correlation with morphology, type of PML gene breakpoint and clinical outcome. A cooperative Italian study on 196 cases. British Journal of Haematology, 1998, 102, 1035-1041.	2.5	184
38	Long-Term Results of a Randomized Trial on Extended Use of High Dose l-Asparaginase for Standard Risk Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2005, 23, 7161-7167.	1.6	180
39	Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. Nature Communications, 2017, 8, 593.	12.8	175
40	An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase. British Journal of Haematology, 2008, 142, 802-807.	2.5	173
41	Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma. Leukemia, 2007, 21, 838-842.	7.2	169
42	Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood, 2013, 122, 170-178.	1.4	162
43	Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder. Lancet, The, 2003, 361, 1617-1620.	13.7	161
44	Large-Cell Medulloblastomas. American Journal of Surgical Pathology, 1992, 16, 687-693.	3.7	158
45	Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. Blood, 2005, 106, 1419-1422.	1.4	152
46	Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 11306-11311.	7.1	151
47	Synthesis and Antitumor Activity of 1,5-Disubstituted 1,2,4-Triazoles as Cis-Restricted Combretastatin Analogues. Journal of Medicinal Chemistry, 2010, 53, 4248-4258.	6.4	149
48	MiR-34a Targeting of Notch Ligand Delta-Like 1 Impairs CD15+/CD133+ Tumor-Propagating Cells and Supports Neural Differentiation in Medulloblastoma. PLoS ONE, 2011, 6, e24584.	2.5	149
49	Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia, 2010, 24, 255-264.	7.2	148
50	Oxygen tension controls the expansion of human CNS precursors and the generation of astrocytes and oligodendrocytes. Molecular and Cellular Neurosciences, 2007, 35, 424-435.	2.2	146
51	Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7. Leukemia, 1999, 13, 376-385.	7.2	142
52	Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. Leukemia, 2007, 21, 706-713.	7.2	139
53	Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia, 2009, 23, 1073-1079.	7.2	137
54	Glioblastoma cancer stem cells: Role of the microenvironment and therapeutic targeting. Biochemical Pharmacology, 2013, 85, 612-622.	4.4	136

#	Article	IF	Citations
55	CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. Blood, 2008, 112, 3982-3988.	1.4	134
56	Interaction of Hypoxia-Inducible Factor-1Î± and Notch Signaling Regulates Medulloblastoma Precursor Proliferation and Fate. Stem Cells, 2010, 28, 1918-1929.	3.2	133
57	Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible. Cytometry Part B - Clinical Cytometry, 2008, 74B, 331-340.	1.5	132
58	BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1Î± stability and MGMT expression. Cell Death and Disease, 2012, 3, e412-e412.	6.3	132
59	Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection. Leukemia, 2005, 19, 49-56.	7.2	129
60	RNA-binding protein IGF2BP3 targeting of oncogenic transcripts promotes hematopoietic progenitor proliferation. Journal of Clinical Investigation, 2016, 126, 1495-1511.	8.2	128
61	miR-34b Targets Cyclic AMPâ€“Responsive Element Binding Protein in Acute Myeloid Leukemia. Cancer Research, 2009, 69, 2471-2478.	0.9	127
62	The Side Population of Ovarian Cancer Cells Is a Primary Target of IFN-Î± Antitumor Effects. Cancer Research, 2008, 68, 5658-5668.	0.9	121
63	Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. Haematologica, 2013, 98, 1702-1710.	3.5	121
64	Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers. Blood, 2011, 117, 902-914.	1.4	119
65	CBFA2T3-GLIS2 fusion transcript is a novel common feature in pediatric, cytogenetically normal AML, not restricted to FAB M7 subtype. Blood, 2013, 121, 3469-3472.	1.4	119
66	CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells. Blood, 2003, 101, 202-209.	1.4	117
67	MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children.. Journal of Clinical Oncology, 1997, 15, 85-93.	1.6	111
68	WT1 mutations in T-ALL. Blood, 2009, 114, 1038-1045.	1.4	111
69	MG-2477, a new tubulin inhibitor, induces autophagy through inhibition of the Akt/mTOR pathway and delayed apoptosis in A549 cells. Biochemical Pharmacology, 2012, 83, 16-26.	4.4	111
70	Synthesis and Evaluation of 1,5-Disubstituted Tetrazoles as Rigid Analogues of Combretastatin A-4 with Potent Antiproliferative and Antitumor Activity. Journal of Medicinal Chemistry, 2012, 55, 475-488.	6.4	109
71	Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts. Leukemia, 2014, 28, 278-288.	7.2	108
72	The lncRNA CASC15 regulates SOX4 expression in RUNX1-rearranged acute leukemia. Molecular Cancer, 2017, 16, 126.	19.2	108

#	Article	IF	Citations
73	Minimal requirements for the diagnosis, classification, and evaluation of the treatment of childhood acute lymphoblastic leukemia (ALL) in the â€œBFM familyâ€•cooperative group. Medical and Pediatric Oncology, 1992, 20, 497-505.	1.0	103
74	Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement. Leukemia, 2007, 21, 633-641.	7.2	102
75	Genetic loss of SH2B3 in acute lymphoblastic leukemia. Blood, 2013, 122, 2425-2432.	1.4	101
76	Hypoxia and HIF1Î± Repress the Differentiative Effects of BMPs in High-Grade Glioma. Stem Cells, 2009, 27, 7-17.	3.2	100
77	Genomic subtyping and therapeutic targeting of acute erythroleukemia. Nature Genetics, 2019, 51, 694-704.	21.4	97
78	Osteonecrosis: An emerging complication of intensive chemotherapy for childhood acute lymphoblastic leukemia. Haematologica, 2003, 88, 747-53.	3.5	97
79	CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease. Leukemia, 2004, 18, 703-708.	7.2	96
80	Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia. Leukemia, 2012, 26, 2245-2253.	7.2	96
81	Lymphocytes subsets reference values in childhood. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2015, 87, 81-85.	1.5	96
82	<scp>AIEOP</scp>â€<scp>BFM</scp> Consensus Guidelines 2016 for Flow Cytometric Immunophenotyping of Pediatric Acute Lymphoblastic Leukemia. Cytometry Part B - Clinical Cytometry, 2018, 94, 82-93.	1.5	96
83	Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia. Haematologica, 2012, 97, 1582-1593.	3.5	95
84	Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis. Lancet Haematology,the, 2016, 3, e80-e86.	4.6	95
85	c-kit Is Expressed in Soft Tissue Sarcoma of Neuroectodermic Origin and Its Ligand Prevents Apoptosis of Neoplastic Cells. Blood, 1998, 91, 2397-2405.	1.4	94
86	Diencephalic syndrome and disseminated juvenile pilocytic astrocytomas of the hypothalamic-optic chiasm region. Cancer, 1997, 80, 142-146.	4.1	92
87	Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Acute Lymphoblastic Leukemia Studies, 1982â€“1995. Leukemia, 2000, 14, 2196-2204.	7.2	92
88	Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II. Blood, 2002, 100, 420-426.	1.4	92
89	Detection of minimal residual disease in pediatric acute lymphoblastic leukemia. Cytometry Part B - Clinical Cytometry, 2013, 84, 359-369.	1.5	92
90	Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-MÃ¼nster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.. Journal of Clinical Oncology, 1995, 13, 2497-2502.	1.6	91

#	Article	IF	Citations
91	Good steroid response in vivo predicts a favorable outcome in children with T-cell acute lymphoblastic leukemia. Cancer, 1995, 75, 1684-1693.	4.1	90
92	Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia. Nature, 2018, 553, 511-514.	27.8	90
93	Wnt activation promotes neuronal differentiation of Glioblastoma. Cell Death and Disease, 2013, 4, e500-e500.	6.3	89
94	Isoindolo[2,1-a]quinoxaline Derivatives, Novel Potent Antitumor Agents with Dual Inhibition of Tubulin Polymerization and Topoisomerase I. Journal of Medicinal Chemistry, 2008, 51, 2387-2399.	6.4	88
95	Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia. British Journal of Haematology, 2009, 144, 930-932.	2.5	88
96	Rearrangements of immunoglobulin and T cell receptor beta and gamma genes are associated with terminal deoxynucleotidyl transferase expression in acute myeloid leukemia.. Journal of Experimental Medicine, 1987, 165, 879-890.	8.5	86
97	Quantitative multiparametric immunophenotyping in acute lymphoblastic leukemia: correlation with specific genotype. I. ETV6/AML1 ALLs identification. Leukemia, 2000, 14, 1225-1231.	7.2	84
98	Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome. Leukemia, 2004, 18, 693-702.	7.2	81
99	Minimal residual disease is an important predictive factor of outcome in children with relapsed â€˜high-riskâ€™ acute lymphoblastic leukemia. Leukemia, 2008, 22, 2193-2200.	7.2	81
100	LncRNA Expression Discriminates Karyotype and Predicts Survival in B-Lymphoblastic Leukemia. Molecular Cancer Research, 2015, 13, 839-851.	3.4	81
101	Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols. Leukemia, 2005, 19, 2043-2053.	7.2	80
102	Early Relapse in ALL Is Identified by Time to Leukemia in NOD/SCID Mice and Is Characterized by a Gene Signature Involving Survival Pathways. Cancer Cell, 2011, 19, 206-217.	16.8	80
103	Synthesis and Biological Evaluation of 2-(Alkoxycarbonyl)-3-Anilinobenzo[b]thiophenes and Thieno[2,3-b]pyridines as New Potent Anticancer Agents. Journal of Medicinal Chemistry, 2013, 56, 2606-2618.	6.4	80
104	Convergent Synthesis and Biological Evaluation of 2-Amino-4-(3â€²,4â€²,5â€²-trimethoxyphenyl)-5-aryl Thiazoles as Microtubule Targeting Agents. Journal of Medicinal Chemistry, 2011, 54, 5144-5153.	6.4	79
105	Somatic PTPN11 mutations in childhood acute myeloid leukaemia. British Journal of Haematology, 2005, 129, 333-339.	2.5	78
106	Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-MÃ¼nster groups.. Journal of Clinical Oncology, 1997, 15, 2786-2791.	1.6	76
107	A mesenchymal chondrosarcoma of a child with the reciprocal translocation (11;22)(q24;q12). Cancer Genetics and Cytogenetics, 1993, 71, 144-147.	1.0	74
108	Expression of Myeloid Markers Lacks Prognostic Impact in Children Treated for Acute Lymphoblastic Leukemia: Italian Experience in AIEOP-ALL 88-91 Studies. Blood, 1998, 92, 795-801.	1.4	74

#	Article	IF	Citations
109	Gene Expressionâ€“Based Classification As an Independent Predictor of Clinical Outcome in Juvenile Myelomonocytic Leukemia. Journal of Clinical Oncology, 2010, 28, 1919-1927.	1.6	74
110	The Three-Layer Concentric Model of Glioblastoma: Cancer Stem Cells, Microenvironmental Regulation, and Therapeutic Implications. Scientific World Journal, The, 2011, 11, 1829-1841.	2.1	74
111	Cytochemical Study of Thymocytes and T Lymphocytes. British Journal of Haematology, 1980, 44, 577-582.	2.5	73
112	N-MYC and C-MYC Oncogenes Amplification in Medulloblastomas. Evidence of Particularly Aggressive Behavior of a Tumor with C-MYC Amplification. Tumori, 1991, 77, 118-121.	1.1	72
113	VIRULENCE GENES AND HOST AND Î² GENES INTERPLAY IN FAVOURING THE DEVELOPMENT OF PEPTIC ULCER AND INTESTINAL METAPLASIA. Cytokine, 2002, 18, 242-251.	3.2	72
114	Exome sequencing identifies putative drivers of progression of transient myeloproliferative disorder to AMKL in infants with Down syndrome. Blood, 2013, 122, 554-561.	1.4	72
115	Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000). Journal of Clinical Oncology, 2018, 36, 244-253.	1.6	71
116	International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia. Blood, 2018, 132, 264-276.	1.4	70
117	Cancer-specific CTCF binding facilitates oncogenic transcriptional dysregulation. Genome Biology, 2020, 21, 247.	8.8	70
118	Long-Term Results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: Insight on the Prognostic Value of DNA Index in the Framework of Berlin-Frankfurt-Muensterâ€“Based Chemotherapy. Journal of Clinical Oncology, 2008, 26, 283-289.	1.6	69
119	Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study. Blood, 2014, 123, 1470-1478.	1.4	69
120	Perceived social support and healthâ€related quality of life in AYA cancer survivors and controls. Psycho-Oncology, 2016, 25, 1408-1417.	2.3	68
121	Phf6 Loss Enhances HSC Self-Renewal Driving Tumor Initiation and Leukemia Stem Cell Activity in T-ALL. Cancer Discovery, 2019, 9, 436-451.	9.4	67
122	USP7 Cooperates with NOTCH1 to Drive the Oncogenic Transcriptional Program in T-Cell Leukemia. Clinical Cancer Research, 2019, 25, 222-239.	7.0	66
123	Determination of extracellular and intracellular pH ofBacillus subtilis suspension under CO2 treatment. Biotechnology and Bioengineering, 2005, 92, 447-451.	3.3	65
124	What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia?. Haematologica, 2013, 98, 1226-1231.	3.5	65
125	JAK/STAT/PKCÎ´ molecular pathways in synovial fluid T lymphocytes reflect the in vivo T helper-17 expansion in psoriatic arthritis. Immunologic Research, 2014, 58, 61-69.	2.9	65
126	Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia. Haematologica, 2015, 100, 935-944.	3.5	64

#	Article	IF	Citations
127	Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Retrospective Multinational Study. Journal of Clinical Oncology, 2019, 37, 770-779.	1.6	64
128	Integration of genomic and gene expression data of childhood ALL without known aberrations identifies subgroups with specific genetic hallmarks. Genes Chromosomes and Cancer, 2009, 48, 22-38.	2.8	62
129	Late Recurrence of Childhood T-Cell Acute Lymphoblastic Leukemia Frequently Represents a Second Leukemia Rather Than a Relapse: First Evidence for Genetic Predisposition. Journal of Clinical Oncology, 2011, 29, 1643-1649.	1.6	62
130	Improvement and extension of anti-EGFR targeting in breast cancer therapy by integration with the Avidin-Nucleic-Acid-Nano-Assemblies. Nature Communications, 2018, 9, 4070.	12.8	62
131	Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, andCDKN2C) in childhood rhabdomyosarcoma. , 1996, 15, 217-222.		61
132	Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down's syndrome, revealing PRAME as a specific discriminating marker. British Journal of Haematology, 2004, 125, 729-742.	2.5	61
133	Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis. Leukemia, 2014, 28, 2197-2205.	7.2	60
134	Mono- and bi-allelic expression of insulin-like growth factor II gene in human muscle tumors. Human Molecular Genetics, 1994, 3, 1117-1121.	2.9	59
135	Interleukin-27 inhibits pediatric B-acute lymphoblastic leukemia cell spreading in a preclinical model. Leukemia, 2011, 25, 1815-1824.	7.2	59
136	Discovery and Optimization of a Series of 2-Aryl-4-Amino-5-(3â€²,4â€²,5â€²-trimethoxybenzoyl)Thiazoles as Novel Anticancer Agents. Journal of Medicinal Chemistry, 2012, 55, 5433-5445.	6.4	57
137	Recent advances in vascular disrupting agents in cancer therapy. Future Medicinal Chemistry, 2014, 6, 1485-1498.	2.3	57
138	Recognition of adult and pediatric acute lymphoblastic leukemia blasts by natural killer cells. Haematologica, 2014, 99, 1248-1254.	3.5	57
139	Expression and parental imprinting of the H19 gene in human rhabdomyosarcoma. Oncogene, 1997, 14, 1503-1510.	5.9	56
140	Monitoring treatment response of childhood precursor B-cell acute lymphoblastic leukemia in the AIEOP-BFM-ALL 2000 protocol with multiparameter flow cytometry: predictive impact of early blast reduction on the remission status after induction. Leukemia, 2009, 23, 528-534.	7.2	56
141	Synthesis and biological evaluation of 2-substituted-4-(3â€²,4â€²,5â€²-trimethoxyphenyl)-5-aryl thiazoles as anticancer agents. Bioorganic and Medicinal Chemistry, 2012, 20, 7083-7094.	3.0	56
142	Frequent cases of RAS-mutated Down syndrome acute lymphoblastic leukaemia lack JAK2 mutations. Nature Communications, 2014, 5, 4654.	12.8	55
143	Effect of Protracted High-Dose l-Asparaginase Given as a Second Exposure in a Berlin-Frankfurt-MÃ¼nsterâ€“Based Treatment: Results of the Randomized 9102 Intermediate-Risk Childhood Acute Lymphoblastic Leukemia Studyâ€”A Report From the Associazione Italiana Ematologia Oncologia Pediatrica. Journal of Clinical Oncology, 2001, 19, 1297-1303.	1.6	54
144	Loss-of-function JAK3 mutations in TMD and AMKL of Down syndrome. British Journal of Haematology, 2007, 137, 337-341.	2.5	54

#	Article	IF	Citations
145	DNA copy-number abnormalities do not occur in infant ALL with t(4;11)/MLL-AF4. Leukemia, 2010, 24, 169-176.	7.2	54
146	Prognostic significance of flowâ€cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the <scp>AIEOP</scp>â€<scp>AML</scp> 2002/01 study protocol. British Journal of Haematology, 2017, 177, 116-126.	2.5	54
147	Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia. Blood, 2017, 130, 2750-2761.	1.4	54
148	2-Arylamino-4-Amino-5-Aroylthiazoles. â€œOne-Potâ€•Synthesis and Biological Evaluation of a New Class of Inhibitors of Tubulin Polymerization. Journal of Medicinal Chemistry, 2009, 52, 5551-5555.	6.4	53
149	TheCOQ2genotype predicts the severity of coenzyme Q₁₀deficiency. Human Molecular Genetics, 2016, 25, 4256-4265.	2.9	53
150	Synthesis, Antimitotic and Antivascular Activity of 1-(3â€²,4â€²,5â€²-Trimethoxybenzoyl)-3-arylamino-5-amino-1,2,4-triazoles. Journal of Medicinal Chemistry, 2014, 57, 6795-6808.	6.4	52
151	Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia. Haematologica, 2003, 88, 1245-52.	3.5	52
152	Acute lymphoblastic leukemia and Down syndrome. Cancer, 2008, 113, 515-521.	4.1	51
153	Prednisone induces immunophenotypic modulation of CD10 and CD34 in nonapoptotic Bâ€cell precursor acute lymphoblastic leukemia cells. Cytometry Part B - Clinical Cytometry, 2008, 74B, 150-155.	1.5	51
154	Two independent gene signatures in pediatric t(4;11) acute lymphoblastic leukemia patients. European Journal of Haematology, 2009, 83, 406-419.	2.2	51
155	Hybrid Î±-bromoacryloylamido chalcones. Design, synthesis and biological evaluation. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 2022-2028.	2.2	50
156	Notch3-mediated regulation of MKP-1 levels promotes survival of T acute lymphoblastic leukemia cells. Leukemia, 2011, 25, 588-598.	7.2	50
157	Computational analysis of flow-cytometry antigen expression profiles in childhood acute lymphoblastic leukemia: an MLL/AF4 identification. Leukemia, 2003, 17, 1557-1565.	7.2	49
158	Functional characterization of human COQ4, a gene required for Coenzyme Q10 biosynthesis. Biochemical and Biophysical Research Communications, 2008, 372, 35-39.	2.1	49
159	Genetic profile of T-cell acute lymphoblastic leukemias with MYC translocations. Blood, 2014, 124, 3577-3582.	1.4	49
160	PDAC-derived exosomes enrich the microenvironment in MDSCs in a SMAD4-dependent manner through a new calcium related axis. Oncotarget, 2017, 8, 84928-84944.	1.8	49
161	cAMP response element binding protein (CREB) overexpression CREB has been described as critical for leukemia progression. Haematologica, 2007, 92, 1435-1437.	3.5	48
162	The micro-RNA 199b-5p regulatory circuit involves Hes1, CD15, and epigenetic modifications in medulloblastoma. Neuro-Oncology, 2012, 14, 596-612.	1.2	48

#	Article	IF	Citations
163	Clonal variegation and dynamic competition of leukemia-initiating cells in infant acute lymphoblastic leukemia with MLL rearrangement. Leukemia, 2015, 29, 38-50.	7.2	48
164	LIN28B overexpression defines a novel fetal-like subgroup of juvenile myelomonocytic leukemia. Blood, 2016, 127, 1163-1172.	1.4	48
165	Clonality profile in relapsed precursor-B-ALL children by GeneScan and sequencing analyses. Consequences on minimal residual disease monitoring. Leukemia, 2003, 17, 1573-1582.	7.2	47
166	Hypoxia and succinate antagonize 2-deoxyglucose effects on glioblastoma. Biochemical Pharmacology, 2010, 80, 1517-1527.	4.4	47
167	Design, Synthesis, in Vitro, and in Vivo Anticancer and Antiangiogenic Activity of Novel 3-Arylaminobenzofuran Derivatives Targeting the Colchicine Site on Tubulin. Journal of Medicinal Chemistry, 2015, 58, 3209-3222.	6.4	47
168	The immunophenotype in infant acute lymphoblastic leukaemia: correlation with clinical outcome. An Italian multicentre study (AIEOP). British Journal of Haematology, 1992, 81, 184-191.	2.5	46
169	Argininosuccinate lyase deficiency: mutational spectrum in Italian patients and identification of a novelASLpseudogene. Human Mutation, 2007, 28, 694-702.	2.5	46
170	Interleukin-23 acts as antitumor agent on childhood B-acute lymphoblastic leukemia cells. Blood, 2010, 116, 3887-3898.	1.4	46
171	Modulation of antigen expression in Bâ€cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: Evidence for a drugâ€induced regulatory phenomenon. Results of the AIEOPâ€BFMâ€ALLâ€FLOWâ€MRDâ€Study Group. Cytometry Part B - Clinical Cytometry, 2010, 78B, 147-153.	1.5	46
172	Individual and combined effect of granulocyte-macrophage colony-stimulating factor and prolactin on maturation of dendritic cells from blood monocytes under serum-free conditions. Immunology, 2000, 100, 29-36.	4.4	45
173	Molecular Mechanisms of HIF-1Î± Modulation Induced by Oxygen Tension and BMP2 in Glioblastoma Derived Cells. PLoS ONE, 2009, 4, e6206.	2.5	45
174	Cytogenetic Analysis of Hepatoblastoma. Cancer Genetics and Cytogenetics, 1998, 104, 39-44.	1.0	44
175	Genetic polymorphism of NAD(P)H:quinone oxidoreductase is associated with an increased risk of infant acute lymphoblastic leukemia without MLL gene rearrangements. Leukemia, 2005, 19, 214-216.	7.2	44
176	Tâ€cell lymphoblastic lymphoma shows differences and similarities with Tâ€cell acute lymphoblastic leukemia by genomic and gene expression analyses. Genes Chromosomes and Cancer, 2011, 50, 1063-1075.	2.8	44
177	Concise Synthesis and Biological Evaluation of 2-Aroyl-5-Amino Benzo[b]thiophene Derivatives As a Novel Class of Potent Antimitotic Agents. Journal of Medicinal Chemistry, 2013, 56, 9296-9309.	6.4	44
178	Preâ€and postâ€transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia. British Journal of Haematology, 2018, 180, 680-693.	2.5	44
179	Pancreatic Tumors and Immature Immunosuppressive Myeloid Cells in Blood and Spleen: Role of Inhibitory Co-Stimulatory Molecules PDL1 and CTLA4. An In Vivo and In Vitro Study. PLoS ONE, 2013, 8, e54824.	2.5	44
180	Central role of mitochondria and p53 in PUVA-induced apoptosis in human keratinocytes cell line NCTC-2544. Toxicology and Applied Pharmacology, 2008, 227, 84-96.	2.8	43

#	Article	IF	Citations
181	Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles. Leukemia, 2011, 25, 1555-1563.	7.2	43
182	Large and Dissimilar Repertoire of Melan-A/MART-1-Specific CTL in Metastatic Lesions and Blood of a Melanoma Patient. Journal of Immunology, 2002, 169, 4017-4024.	0.8	42
183	Synthesis and biological evaluation of 2-(3â€²,4â€²,5â€²-trimethoxybenzoyl)-3-aryl/arylaminobenzo[b]thiophene derivatives as a novel class of antiproliferative agents. European Journal of Medicinal Chemistry, 2010, 45, 5781-5791.	5.5	42
184	Functional Protein Network Activation Mapping Reveals New Potential Molecular Drug Targets for Poor Prognosis Pediatric BCP-ALL. PLoS ONE, 2010, 5, e13552.	2.5	42
185	MicroRNA-34b promoter hypermethylation induces CREB overexpression and contributes to myeloid transformation. Haematologica, 2013, 98, 602-610.	3.5	42
186	CD371 cell surface expression: a unique feature of DUX4-rearranged acute lymphoblastic leukemia. Haematologica, 2019, 104, e352-e355.	3.5	42
187	Analysis of CDKN2A, CDKN2B, CDKN2C, and cyclin Ds gene status in hepatoblastoma. Hepatology, 1998, 27, 989-995.	7.3	41
188	MLL-AF6 fusion oncogene sequesters AF6 into the nucleus to trigger RAS activation in myeloid leukemia. Blood, 2014, 124, 263-272.	1.4	41
189	Autologous bone marrow transplantation for treatment of isolated central nervous system relapse of childhood acute lymphoblastic leukemia. Bone Marrow Transplantation, 1998, 21, 9-14.	2.4	40
190	Prognostic Role of Minimal Residual Disease in Mature B-Cell Acute Lymphoblastic Leukemia of Childhood. Journal of Clinical Oncology, 2007, 25, 5254-5261.	1.6	40
191	Pyrrolo[3,4-h]quinolinones a new class of photochemotherapeutic agents. Bioorganic and Medicinal Chemistry, 2011, 19, 2326-2341.	3.0	40
192	AMPK inhibition enhances apoptosis in MLL-rearranged pediatric B-acute lymphoblastic leukemia cells. Leukemia, 2013, 27, 1019-1027.	7.2	40
193	Core-binding factor acute myeloid leukemia in pediatric patients enrolled in the AIEOP AML 2002/01 trial: screening and prognostic impact of c-KIT mutations. Leukemia, 2014, 28, 1132-1134.	7.2	40
194	Design, synthesis and biological evaluation of 3,5-disubstituted 2-amino thiophene derivatives as a novel class of antitumor agents. Bioorganic and Medicinal Chemistry, 2014, 22, 5097-5109.	3.0	40
195	Characterization of two patients with lymphomas of large granular lymphocytes. Cancer, 1984, 53, 445-452.	4.1	39
196	The common TEL/AML1 rearrangement does not represent a frequent event in acute lymphoblastic leukaemia occurring in children with Down syndrome. Leukemia, 1997, 11, 820-821.	7.2	39
197	Induction of Î³-globin mRNA, erythroid differentiation and apoptosis in UVA-irradiated human erythroid cells in the presence of furocumarin derivatives. Biochemical Pharmacology, 2008, 75, 810-825.	4.4	39
198	Outcomes of Children with Hemophagocytic Lymphohistiocytosis Given Allogeneic Hematopoietic Stem Cell Transplantation in Italy. Biology of Blood and Marrow Transplantation, 2018, 24, 1223-1231.	2.0	39

#	Article	IF	Citations
199	Apoptosis and phosphatidylserine-mediated recognition during the take-over phase of the colonial life-cycle in the ascidian Botryllus schlosseri. Cell and Tissue Research, 2003, 312, 369-376.	2.9	38
200	Haemocytes and blastogenetic cycle in the colonial ascidian Botryllus schlosseri: a matter of life and death. Cell and Tissue Research, 2008, 331, 555-564.	2.9	38
201	Post-traumatic Stress Symptoms and Post-traumatic Growth in 223 Childhood Cancer Survivors: Predictive Risk Factors. Frontiers in Psychology, 2016, 7, 287.	2.1	38
202	Cytogenetic t(11;17)(q13;q21) in a pediatric ependymoma. Cancer Genetics and Cytogenetics, 1992, 59, 213-216.	1.0	37
203	Design, Synthesis, and Structureâ€“Activity Relationships of Azolylmethylpyrroloquinolines as Nonsteroidal Aromatase Inhibitors. Journal of Medicinal Chemistry, 2013, 56, 7536-7551.	6.4	37
204	Treatment of Acute Graft-versus-Host Disease in Childhood with Extracorporeal Photochemotherapy/Photopheresis: TheÂPadova Experience. Biology of Blood and Marrow Transplantation, 2015, 21, 1963-1972.	2.0	37
205	Detection of prognostic factors in children and adolescents with Burkitt and Diffuse Large Bâ€Cell Lymphoma treated with the <scp>AIEOP LNH</scp>â€97 protocol. British Journal of Haematology, 2016, 175, 467-475.	2.5	37
206	Posttranslational Regulation of the Exon Skipping Machinery Controls Aberrant Splicing in Leukemia. Cancer Discovery, 2020, 10, 1388-1409.	9.4	37
207	CD10 is a marker for cycling cells with propensity to apoptosis in childhood ALL. British Journal of Cancer, 2002, 86, 1776-1785.	6.4	36
208	Transcriptional network profile on synovial fluid T cells in psoriatic arthritis. Clinical Rheumatology, 2015, 34, 1571-1580.	2.2	36
209	Targeting Glioblastoma with the Use of Phytocompounds and Nanoparticles. Targeted Oncology, 2016, 11, 1-16.	3.6	36
210	Late mortality and causes of death among 5-year survivors of childhood cancer diagnosed in the period 1960â€“1999 and registered in the Italian Off-Therapy Registry. European Journal of Cancer, 2019, 110, 86-97.	2.8	36
211	Coagulation Activation in Children with Sickle Cell Disease Is Associated with Cerebral Small Vessel Vasculopathy. PLoS ONE, 2013, 8, e78801.	2.5	36
212	Integrin expression and IgA nephropathy: In vitro modulation by IgA with altered glycosylation and macromolecular IgA11See Editorial by Steffes, p. 2592. Kidney International, 2000, 58, 2331-2340.	5.2	35
213	MLL rearrangements in pediatric acute lymphoblastic and myeloblastic leukemias: MLL specific and lineage specific signatures. BMC Medical Genomics, 2009, 2, 36.	1.5	35
214	Validation of flow cytometric phospho-STAT5 as a diagnostic tool for juvenile myelomonocytic leukemia. Blood Cancer Journal, 2013, 3, e160-e160.	6.2	35
215	Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangement. Haematologica, 2015, 100, e99-e101.	3.5	35
216	Clinical features and outcome of SIL/TAL1-positive T-cell acute lymphoblastic leukemia in children and adolescents: a 10-year experience of the AIEOP group. Haematologica, 2015, 100, e10-e13.	3.5	35

#	Article	IF	Citations
217	NUP98-fusion transcripts characterize different biological entities within acute myeloid leukemia: a report from the AIEOP-AML group. Leukemia, 2017, 31, 974-977.	7.2	35
218	Vanillic Acid Restores Coenzyme Q Biosynthesis and ATP Production in Human Cells LackingCOQ6. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-11.	4.0	35
219	BAG1: The Guardian of Anti-Apoptotic Proteins in Acute Myeloid Leukemia. PLoS ONE, 2011, 6, e26097.	2.5	35
220	Co-expression of myeloid antigens in childhood acute lymphoblastic leukaemia: relationship with the stage of differentiation and clinical significance. British Journal of Haematology, 1991, 79, 40-43.	2.5	34
221	Prospective molecular monitoring of BCR/ABL transcript in children with Ph+ acute lymphoblastic leukaemia unravels differences in treatment response. British Journal of Haematology, 2002, 119, 445-453.	2.5	34
222	Natural daucane sesquiterpenes with antiproliferative and proapoptotic activity against human tumor cells. Bioorganic and Medicinal Chemistry, 2011, 19, 5876-5885.	3.0	34
223	MGMT expression and promoter methylation status may depend on the site of surgical sample collection within glioblastoma: a possible pitfall in stratification of patients?. Journal of Neuro-Oncology, 2012, 106, 33-41.	2.9	34
224	Neuroblastoma tumorigenesis is regulated through the Nm23-H1/h-Prune C-terminal interaction. Scientific Reports, 2013, 3, 1351.	3.3	34
225	Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene. Journal of Hematology and Oncology, 2017, 10, 26.	17.0	34
226	Cytogenetics of pediatric central nervous system tumors. Cancer Genetics and Cytogenetics, 1996, 91, 13-27.	1.0	33
227	Immunogenotype Changes Prevail in Relapses of Young Children with TEL-AML1-Positive Acute Lymphoblastic Leukemia and Derive Mainly from Clonal Selection. Clinical Cancer Research, 2005, 11, 7720-7727.	7.0	33
228	Expression and Functional Analysis of Human Leukocyte Antigen Class I Antigen-Processing Machinery in Medulloblastoma. Cancer Research, 2007, 67, 5471-5478.	0.9	33
229	Hovering between death and life: Natural apoptosis and phagocytes in the blastogenetic cycle of the colonial ascidian Botryllus schlosseri. Developmental and Comparative Immunology, 2010, 34, 272-285.	2.3	33
230	TR-644 a novel potent tubulin binding agent induces impairment of endothelial cells function and inhibits angiogenesis. Angiogenesis, 2013, 16, 647-662.	7.2	33
231	Characterization and transcription studies of a phytochelatin synthase gene from the solitary tunicate Ciona intestinalis exposed to cadmium. Aquatic Toxicology, 2014, 152, 47-56.	4.0	33
232	Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols. Haematologica, 2020, 105, 1887-1894.	3.5	33
233	Prognostic value of rhodamine-efflux and MDR-1/P-170 expression in childhood acute leukemia. Leukemia Research, 1995, 19, 927-931.	0.8	32
234	One-pot synthesis and biological evaluation of 2-pyrrolidinyl-4-amino-5-(3â€²,4â€²,5â€²-trimethoxybenzoyl)thiazole: A unique, highly active antimicrotubule agent. European Journal of Medicinal Chemistry, 2011, 46, 6015-6024.	5.5	32

#	Article	IF	Citations
235	Detection and role of minimal disseminated disease in children with lymphoblastic lymphoma: The AIEOP experience. Pediatric Blood and Cancer, 2015, 62, 1906-1913.	1.5	32
236	HSP70/HSF1 axis, regulated via a PI3K/AKT pathway, is a druggable target in chronic lymphocytic leukemia. International Journal of Cancer, 2019, 145, 3089-3100.	5.1	32
237	Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia. Nature Cancer, 2020, 1, 1113-1127.	13.2	32
238	Tubulointerstitial responses in the progression of glomerular diseases: Albuminuria modulates Î±vÎ²5 integrin. Kidney International, 1996, 50, 1310-1320.	5.2	31
239	Chemokine receptor expression and function in childhood acute lymphoblastic leukemia of B-lineage. Leukemia Research, 2006, 30, 365-372.	0.8	31
240	MLL partner genes drive distinct gene expression profiles and genomic alterations in pediatric acute myeloid leukemia: an AIEOP study. Leukemia, 2011, 25, 560-563.	7.2	31
241	Development of a pluripotent stem cell derived neuronal model to identify chemically induced pathway perturbations in relation to neurotoxicity: Effects of CREB pathway inhibition. Toxicology and Applied Pharmacology, 2014, 280, 378-388.	2.8	31
242	AKR1C enzymes sustain therapy resistance in paediatric T-ALL. British Journal of Cancer, 2018, 118, 985-994.	6.4	31
243	Health-related quality of life in AYA cancer survivors who underwent HSCT compared with healthy peers. European Journal of Cancer Care, 2018, 27, e12878.	1.5	31
244	Serum miRNA Are Promising Biomarkers for the Detection of Early Hepatocellular Carcinoma after Treatment with Direct-Acting Antivirals. Cancers, 2019, 11, 1773.	3.7	31
245	Latent hepatitis B virus infection in childhood hepatocellular carcinoma analysis by polymerase chain reaction. Cancer, 1992, 69, 2731-2735.	4.1	30
246	Cell Adhesion Molecule Expression in Cord Blood CD34 ⁺ Cells. Stem Cells, 1998, 16, 120-126.	3.2	30
247	Proapoptotic effect of hepatitis C virus CORE protein in transiently transfected cells is enhanced by nuclear localization and is dependent on PKR activation. Journal of Hepatology, 2004, 40, 77-85.	3.7	30
248	Functional Complementation in Yeast Allows Molecular Characterization of Missense Argininosuccinate Lyase Mutations. Journal of Biological Chemistry, 2009, 284, 28926-28934.	3.4	30
249	Advanced pediatric myelodysplastic syndromes: Can immunophenotypic characterization of blast cells be a diagnostic and prognostic tool?. Pediatric Blood and Cancer, 2009, 52, 357-363.	1.5	30
250	Hematopoietic stem cell transplantation for children with high-risk acute lymphoblastic leukemia in first complete remission: a report from the AIEOP registry. Haematologica, 2013, 98, 1273-1281.	3.5	30
251	Phenotypic and functional characterization of Glioblastoma cancer stem cells identified trough 5-aminolevulinic acid-assisted surgery. Journal of Neuro-Oncology, 2014, 116, 505-513.	2.9	30
252	Focal nodular hyperplasia of the liver: an emerging complication of hematopoietic SCT in children. Bone Marrow Transplantation, 2015, 50, 414-419.	2.4	30

#	Article	IF	Citations
253	The presence of mutated and deleted <scp>PTEN</scp> is associated with an increased risk of relapse in childhood T cell acute lymphoblastic leukaemia treated with <scp>AIEOP</scp>â€<scp>BFM ALL</scp> protocols. British Journal of Haematology, 2018, 182, 705-711.	2.5	30
254	Dexamethasone in Induction Can Eliminate One Third of All Relapses in Childhood Acute Lymphoblastic Leukemia (ALL): Results of An International Randomized Trial in 3655 Patients (Trial AIEOP-BFM ALL) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	g.8	30
255	MicroRNA fingerprints in juvenile myelomonocytic leukemia (JMML) identified miR-150-5p as a tumor suppressor and potential target for treatment. Oncotarget, 2016, 7, 55395-55408.	1.8	30
256	Reversal of the glycolytic phenotype of primary effusion lymphoma cells by combined targeting of cellular metabolism and PI3K/Akt/ mTOR signaling. Oncotarget, 2016, 7, 5521-5537.	1.8	30
257	High incidence and unique features of antigen receptor gene rearrangements in TELâ€“AML1-positive leukemias. Leukemia, 2004, 18, 84-91.	7.2	29
258	Copper and bezafibrate cooperate to rescue cytochrome c oxidase deficiency in cells of patients with sco2 mutations. Orphanet Journal of Rare Diseases, 2012, 7, 21.	2.7	29
259	Fine tuning of surface CRLF2 expression and its associated signaling profile in childhood B-cell precursor acute lymphoblastic leukemia. Haematologica, 2015, 100, e229-e232.	3.5	29
260	Ex Vivo Signaling Protein Mapping in T Lymphocytes in the Psoriatic Arthritis Joints. Journal of rheumatology Supplement, The, 2015, 93, 48-52.	2.2	29
261	Design and Synthesis of Potent in Vitro and in Vivo Anticancer Agents Based on 1-(3â€²,4â€²,5â€²-Trimethoxyphenyl)-2-Aryl-1H-Imidazole. Scientific Reports, 2016, 6, 26602.	3.3	29
262	Characterization of children with FLT3-ITD acute myeloid leukemia: a report from the AIEOP AML-2002 study group. Leukemia, 2017, 31, 18-25.	7.2	29
263	TP-0903 inhibits neuroblastoma cell growth and enhances the sensitivity to conventional chemotherapy. European Journal of Pharmacology, 2018, 818, 435-448.	3.5	29
264	HIF-1Î±/Wnt signaling-dependent control of gene transcription regulates neuronal differentiation of glioblastoma stem cells. Theranostics, 2019, 9, 4860-4877.	10.0	29
265	Annexin 2A sustains glioblastoma cell dissemination and proliferation. Oncotarget, 2016, 7, 54632-54649.	1.8	29
266	Effects of CD2 locus control region sequences on gene expression by retroviral and lentiviral vectors. Blood, 2001, 98, 3607-3617.	1.4	28
267	hCOX18 and hCOX19: Two human genes involved in cytochrome c oxidase assembly. Biochemical and Biophysical Research Communications, 2005, 337, 832-839.	2.1	28
268	Postinduction Minimal Residual Disease Monitoring by Polymerase Chain Reaction in Children With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2014, 32, 3553-3558.	1.6	28
269	CREB engages C/EBPÎ´ to initiate leukemogenesis. Leukemia, 2016, 30, 1887-1896.	7.2	28
270	Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol. Pharmacogenomics Journal, 2017, 17, 4-10.	2.0	28

#	Article	IF	Citations
271	Treosulfan-based conditioning regimen in sibling and alternative donor hematopoietic stem cell transplantation for children with sickle cell disease. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 9, e2017014.	1.3	27
272	Phosphoproteomic analysis reveals hyperactivation of mTOR/STAT3 and LCK/Calcineurin axes in pediatric early T-cell precursor ALL. Leukemia, 2017, 31, 1007-1011.	7.2	27
273	Self-Esteem and Academic Difficulties in Preadolescents and Adolescents Healed from Paediatric Leukaemia. Cancers, 2017, 9, 55.	3.7	27
274	Ribociclib, a Cdk4/Cdk6 kinase inhibitor, enhances glucocorticoid sensitivity in B-acute lymphoblastic leukemia (B-All). Biochemical Pharmacology, 2018, 153, 230-241.	4.4	27
275	Genetic risk factors for VIPN in childhood acute lymphoblastic leukemia patients identified using whole-exome sequencing. Pharmacogenomics, 2018, 19, 1181-1193.	1.3	27
276	BMP9 counteracts the tumorigenic and pro-angiogenic potential of glioblastoma. Cell Death and Differentiation, 2018, 25, 1808-1822.	11.2	27
277	Role of treatment intensification in infants with acute lymphoblastic leukemia: results of two consecutive AIEOP studies. Haematologica, 2006, 91, 534-7.	3.5	27
278	A NOVEL VARIANT TRANSLOCATION t(2;13) (p23;q34) IN Ki-1 LARGE CELL ANAPLASTIC LYMPHOMA. British Journal of Haematology, 1990, 75, 621-622.	2.5	26
279	Outcome and lineage involvement in t(12;21) childhood acute lymphoblastic leukaemia. British Journal of Haematology, 1997, 97, 460-462.	2.5	26
280	Methylation of the IL-12RÎ²2 Gene as Novel Tumor Escape Mechanism for Pediatric B-Acute Lymphoblastic Leukemia Cells. Cancer Research, 2006, 66, 3978-3980.	0.9	26
281	CD11b is a therapy resistanceâ€“ and minimal residual diseaseâ€“specific marker in precursor B-cell acute lymphoblastic leukemia. Blood, 2010, 115, 3763-3771.	1.4	26
282	Infants with acute myeloid leukemia treated according to the Associazione Italiana di Ematologia e Oncologia Pediatrica 2002/01 protocol have an outcome comparable to that of older children. Haematologica, 2014, 99, e127-e129.	3.5	26
283	New Pyrimido-Indole Compound CD-160130 Preferentially Inhibits the K_V11.1B Isoform and Produces Antileukemic Effects without Cardiotoxicity. Molecular Pharmacology, 2015, 87, 183-196.	2.3	26
284	A leukemia-enriched cDNA microarray platform identifies new transcripts with relevance to the biology of pediatric acute lymphoblastic leukemia. Haematologica, 2005, 90, 890-8.	3.5	26
285	Comprehensive care for sickle cell disease immigrant patients: A reproducible model achieving high adherence to minimum standards of care. Pediatric Blood and Cancer, 2012, 59, 1275-1279.	1.5	25
286	Detection of PICALM-MLLT10 (CALM-AF10) and outcome in children with T-lineage acute lymphoblastic leukemia. Leukemia, 2013, 27, 2419-2421.	7.2	25
287	Longâ€term results of the AIEOP LNHâ€97 protocol for childhood lymphoblastic lymphoma. Pediatric Blood and Cancer, 2015, 62, 1388-1394.	1.5	25
288	COX16 is required for assembly of cytochrome c oxidase in human cells and is involved in copper delivery to COX2. Biochimica Et Biophysica Acta - Bioenergetics, 2018, 1859, 244-252.	1.0	25

#	Article	IF	Citations
289	LIN28B increases neural crest cell migration and leads to transformation of trunk sympathoadrenal precursors. Cell Death and Differentiation, 2020, 27, 1225-1242.	11.2	25
290	A novel copper(I) complex induces ER-stress-mediated apoptosis and sensitizes B-acute lymphoblastic leukemia cells to chemotherapeutic agents. Oncotarget, 2014, 5, 5978-5991.	1.8	25
291	Clinical relevance of DNA ploidy and proliferative activity in childhood rhabdomyosarcoma: a retrospective analysis of patients enrolled onto the Italian Cooperative Rhabdomyosarcoma Study RMS88.. Journal of Clinical Oncology, 1997, 15, 1198-1205.	1.6	24
292	Autologous bone marrow transplantation for childhood acute lymphoblastic leukaemia in Italy. Bone Marrow Transplantation, 1998, 21, 1015-1021.	2.4	24
293	Hepatoblastoma: DNA nuclear content, proliferative indices, and pathology. Liver, 1998, 18, 128-133.	0.1	24
294	Identification of somatic and germline mutations using whole exome sequencing of congenital acute lymphoblastic leukemia. BMC Cancer, 2013, 13, 55.	2.6	24
295	FOXO3a and Posttranslational Modifications Mediate Glucocorticoid Sensitivity in B-ALL. Molecular Cancer Research, 2015, 13, 1578-1590.	3.4	24
296	Are all cases of paediatric essential thrombocythaemia really myeloproliferative neoplasms? Analysis of a large cohort. British Journal of Haematology, 2015, 169, 584-589.	2.5	24
297	Eltrombopag use in a patient with Wiskottâ€“Aldrich syndrome. Pediatric Blood and Cancer, 2017, 64, e26692.	1.5	24
298	Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial. Leukemia, 2020, 34, 1694-1700.	7.2	24
299	Cognition and the Default Mode Network in Children with Sickle Cell Disease: A Resting State Functional MRI Study. PLoS ONE, 2016, 11, e0157090.	2.5	24
300	CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia. Oncotarget, 2016, 7, 59260-59272.	1.8	24
301	An Extensive Quality Control and Quality Assurance (QC/QA) Program Significantly Improves Inter-Laboratory Concordance Rates of Flow-Cytometric Minimal Residual Disease Assessment in Acute Lymphoblastic Leukemia: An I-BFM-FLOW-Network Report. Cancers, 2021, 13, 6148.	3.7	24
302	Unique genotypic features of infant acute lymphoblastic leukaemia at presentation and at relapse. British Journal of Haematology, 1992, 80, 472-479.	2.5	23
303	Flt-3 and Its Ligand Are Expressed in Neural Crestâ€“Derived Tumors and Promote Survival and Proliferation of Their Cell Lines. Laboratory Investigation, 2001, 81, 1025-1037.	3.7	23
304	The Phototoxicity of Fluvastatin, an HMG-CoA Reductase Inhibitor, Is Mediated by the formation of a Benzocarbazole-Like Photoproduct. Toxicological Sciences, 2010, 118, 236-250.	3.1	23
305	Functional Analysis of Missense Mutations ofOAT, Causing Gyrate Atrophy of Choroid and Retina. Human Mutation, 2013, 34, 229-236.	2.5	23
306	Natural daucane esters induces apoptosis in leukaemic cells through ROS production. Phytochemistry, 2014, 108, 147-156.	2.9	23

#	Article	IF	Citations
307	Inhibition of PI3K Signalling Selectively Affects Medulloblastoma Cancer Stem Cells. BioMed Research International, 2015, 2015, 1-11.	1.9	23
308	Novel 3-Substituted 7-Phenylpyrrolo[3,2-f]quinolin-9(6H)-ones as Single Entities with Multitarget Antiproliferative Activity. Journal of Medicinal Chemistry, 2015, 58, 7991-8010.	6.4	23
309	Genomic complexity and dynamics of clonal evolution in childhood acute myeloid leukemia studied with whole-exome sequencing. Oncotarget, 2016, 7, 56746-56757.	1.8	23
310	Design, synthesis and biological evaluation of 3-substituted-2-oxindole hybrid derivatives as novel anticancer agents. European Journal of Medicinal Chemistry, 2017, 134, 258-270.	5.5	23
311	Selective killing of human T-ALL cells: an integrated approach targeting redox homeostasis and the OMA1/OPA1 axis. Cell Death and Disease, 2018, 9, 822.	6.3	23
312	DHH-RHEBL1fusion transcript: a novel recurrent feature in the new landscape of pediatricCBFA2T3-GLIS2-positive acute myeloid leukemia. Oncotarget, 2013, 4, 1712-1720.	1.8	23
313	Therapy-resistant acute lymphoblastic leukemia (ALL) cells inactivate FOXO3 to escape apoptosis induction by TRAIL and Noxa. Oncotarget, 2013, 4, 995-1007.	1.8	23
314	Lack of p73 expression in mature B-ALL and identification of three new splicing variants restricted to pre B and C-ALL indicate a role of p73 in B cell ALL differentiation. Leukemia, 2000, 14, 518-519.	7.2	22
315	Therapeutic Effectiveness of Recombinant Cancer Vaccines Is Associated with a Prevalent T-Cell Receptor Î± Usage by Melanoma-specific CD8+ T Lymphocytes. Cancer Research, 2004, 64, 8068-8076.	0.9	22
316	The MIF-173G/C polymorphism does not contribute to prednisone poor response in vivo in childhood acute lymphoblastic leukemia. Leukemia, 2005, 19, 2346-2347.	7.2	22
317	Risk-directed therapy for childhood acute lymphoblastic leukemia. Results of the associazione italiana ematologia oncologia pediatrica '82 studies. Cancer, 1993, 72, 2517-2524.	4.1	21
318	Immunohistochemical Distribution of Endothelin in Biopsies of Pediatric Nephrotic Syndrome. American Journal of Nephrology, 1994, 14, 157-161.	3.1	21
319	Fluorescent in situ hybridization (FISH) reveals frequent and recurrent numerical and structural abnormalities in hepatoblastoma with no informative karyotype. Medical and Pediatric Oncology, 2002, 39, 536-539.	1.0	21
320	Intellectual function evaluation of first generation immigrant children with sickle cell disease: the role of language and sociodemographic factors. Italian Journal of Pediatrics, 2013, 39, 36.	2.6	21
321	Design, synthesis, crystallization and biological evaluation of new symmetrical biscationic compounds as selective inhibitors of human Choline Kinase Î±1 (ChoKÎ±1). Scientific Reports, 2016, 6, 23793.	3.3	21
322	Sex-dependent differences in inflammatory responses during liver regeneration in a murine model of acute liver injury. Clinical Science, 2018, 132, 255-272.	4.3	21
323	ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia. Oncotarget, 2017, 8, 26129-26141.	1.8	21
324	Mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia: a report from the Italian AIEOP study group. Oncotarget, 2016, 7, 28914-28919.	1.8	21

#	Article	IF	Citations
325	WT1 loss attenuates the TP53-induced DNA damage response in T-cell acute lymphoblastic leukemia. Haematologica, 2018, 103, 266-277.	3.5	21
326	Molecular and immunological evidence of B-cell commitment in â€œnullâ€•acute lymphoblastic leukaemia. International Journal of Cancer, 1986, 38, 317-323.	5.1	20
327	The Role of Immunophenotype in Acute Lymphoblastic Leukemia of Infant Age. Leukemia and Lymphoma, 1994, 15, 51-60.	1.3	20
328	Photophysical Properties and Photobiological Behavior of Amodiaquine, Primaquine and Chloroquine. Photochemistry and Photobiology, 2007, 83, 1415-1427.	2.5	20
329	ICER expression inhibits leukemia phenotype and controls tumor progression. Leukemia, 2008, 22, 2217-2225.	7.2	20
330	Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia. Leukemia, 2011, 25, 1365-1368.	7.2	20
331	A therapeutic approach to treat prostate cancer by targeting Nm23-H1/h-Prune interaction. Naunyn-Schmiedeberg's Archives of Pharmacology, 2015, 388, 257-269.	3.0	20
332	Recurrent phagocytosis-induced apoptosis in the cyclical generation change of the compound ascidian Botryllus schlosseri. Developmental and Comparative Immunology, 2016, 62, 8-16.	2.3	20
333	Deciphering KRAS and NRAS mutated clone dynamics in MLL-AF4 paediatric leukaemia by ultra deep sequencing analysis. Scientific Reports, 2016, 6, 34449.	3.3	20
334	Risk Factors and Outcomes Related to Pediatric Intensive Care Unit Admission after Hematopoietic Stem Cell Transplantation: A Single-Center Experience. Biology of Blood and Marrow Transplantation, 2017, 23, 1335-1341.	2.0	20
335	Droplet Digital PCR Improves IG-/TR-based MRD Risk Definition in Childhood B-cell Precursor Acute Lymphoblastic Leukemia. HemaSphere, 2021, 5, e543.	2.7	20
336	Low PKCÎ± expression within the MRD-HR stratum defines a new subgroup of childhood T-ALL with very poor outcome. Oncotarget, 2014, 5, 5234-5245.	1.8	20
337	Validation of NG2 antigen in identifying BP-ALL patients with MLL rearrangements using qualitative and quantitative flow cytometry: a prospective study. Leukemia, 2008, 22, 858-861.	7.2	19
338	Synthesis and Biological Evaluation of New Geiparvarin Derivatives. ChemMedChem, 2009, 4, 769-779.	3.2	19
339	FOXM1 is overexpressed in B-acute lymphoblastic leukemia (B-ALL) and its inhibition sensitizes B-ALL cells to chemotherapeutic drugs. International Journal of Oncology, 2015, 47, 1230-1240.	3.3	19
340	EB-3D a novel choline kinase inhibitor induces deregulation of the AMPK-mTOR pathway and apoptosis in leukemia T-cells. Biochemical Pharmacology, 2018, 155, 213-223.	4.4	19
341	High expression of miR-125b-2 and SNORD116 noncoding RNA clusters characterize ERG-related B cell precursor acute lymphoblastic leukemia. Oncotarget, 2017, 8, 42398-42413.	1.8	19
342	The effects of siRNA-mediated inhibition of E2A-PBX1 on EB-1 and Wnt16b expression in the 697 pre-B leukemia cell line. Haematologica, 2006, 91, 765-71.	3.5	19

#	Article	IF	Citations
343	Prognostic relevance of pretreatment proliferative rapidity of marrow blast cells in childhood acute lymphoblastic leukaemia. British Journal of Cancer, 1994, 70, 1198-1202.	6.4	18
344	A single high dose of idarubicin combined with high-dose ARA-C for treatment of first relapse in childhood â€˜high-riskâ€™ acute lymphoblastic leukaemia: a study of the AIEOP group. British Journal of Haematology, 2002, 118, 741-747.	2.5	18
345	DLXgenes as targets ofALL-1:DLX2,3,4 down-regulation in t(4;11) acute lymphoblastic leukemias. Journal of Leukocyte Biology, 2003, 74, 302-305.	3.3	18
346	Synthesis and photochemotherapeutic activity of thiopyrano[2,3-e]indol-2-ones. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 2291-2294.	2.2	18
347	Induction of apoptosis in Jurkat cells by photoexcited psoralen derivatives: Implication of mitochondrial dysfunctions and caspases activation. Toxicology in Vitro, 2007, 21, 211-216.	2.4	18
348	Differential expression of hERG1A and hERG1B genes in pediatric acute lymphoblastic leukemia identifies different prognostic subgroups. Leukemia, 2014, 28, 1352-1355.	7.2	18
349	Outcome of children with acute myeloid leukaemia (<scp>AML</scp>) experiencing primary induction failure in the <scp>AIEOP AML</scp> 2002/01 clinical trial. British Journal of Haematology, 2015, 171, 566-573.	2.5	18
350	Refinement of IKZF1 status in pediatric Philadelphia-positive acute lymphoblastic leukemia. Leukemia, 2015, 29, 2107-2110.	7.2	18
351	Kinetics of Circulating Plasma Cell-Free DNA in Paediatric Classical Hodgkin Lymphoma. Journal of Cancer, 2016, 7, 364-366.	2.5	18
352	Development of Lentiviral Vectors Simultaneously Expressing Multiple siRNAs Against CCR5, vif and tat/rev Genes for an HIV-1 Gene Therapy Approach. Molecular Therapy - Nucleic Acids, 2016, 5, e312.	5.1	18
353	Deletions of the long arm of chromosome 5 define subgroups of T-cell acute lymphoblastic leukemia. Haematologica, 2016, 101, 951-958.	3.5	18
354	Antileukemic Efficacy of BET Inhibitor in a Preclinical Mouse Model of MLL-AF4+ Infant ALL. Molecular Cancer Therapeutics, 2018, 17, 1705-1716.	4.1	18
355	Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma. Haematologica, 2019, 104, e17-e20.	3.5	18
356	Flowâ€cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric Bâ€cell precursor acute lymphoblastic leukemia in trial AIEOPâ€BFMâ€ALL 2000. Pediatric Blood and Cancer, 2019, 66, e27590.	1.5	18
357	Design of a Comprehensive Fluorescence in Situ Hybridization Assay for Genetic Classification of T-Cell Acute Lymphoblastic Leukemia. Journal of Molecular Diagnostics, 2020, 22, 629-639.	2.8	18
358	Increased levels of a chromosome 21-encoded tumour invasion and metastasis factor(TIAM1) mRNA in bone marrow of down syndrome children during the acute phase of AML(M7). , 1998, 23, 61-66.		17
359	Induction of apoptosis by photoexcited tetracyclic compounds derivatives of benzo[b]thiophenes and pyridines. Journal of Photochemistry and Photobiology B: Biology, 2006, 82, 105-116.	3.8	17
360	Hepatocyte Growth Factor Receptor c-MET Is Associated with FAS and When Activated Enhances Drug-induced Apoptosis in Pediatric B Acute Lymphoblastic Leukemia with TEL-AML1 Translocation. Journal of Biological Chemistry, 2007, 282, 29384-29393.	3.4	17

#	Article	IF	Citations
361	Synthesis and inâ€...vitro Evaluation of 3Hâ€Pyrrolo[3,2â€f]quinolinâ€9â€one Derivatives That Show Potent and Selective Antiâ€leukemic Activity. ChemMedChem, 2010, 5, 1373-1385.	3.2	17
362	PTPN11 mutations in childhood acute lymphoblastic leukemia occur as a secondary event associated with high hyperdiploidy. Leukemia, 2010, 24, 232-235.	7.2	17
363	Novel 9â€²-substituted-noscapines: Synthesis with Suzuki cross-coupling, structure elucidation and biological evaluation. European Journal of Medicinal Chemistry, 2014, 84, 476-490.	5.5	17
364	Design, synthesis and biological evaluation of arylcinnamide hybrid derivatives as novel anticancer agents. European Journal of Medicinal Chemistry, 2014, 81, 394-407.	5.5	17
365	LCKover-expression drives STAT5 oncogenic signaling inPAX5translocated BCP-ALL patients. Oncotarget, 2015, 6, 1569-1581.	1.8	17
366	Vascular disrupting activity of combretastatin analogues. Vascular Pharmacology, 2016, 83, 78-89.	2.1	17
367	Synthesis and Biological Evaluation of 2-Methyl-4,5-Disubstituted Oxazoles as a Novel Class of Highly Potent Antitubulin Agents. Scientific Reports, 2017, 7, 46356.	3.3	17
368	A synthetic BMP-2 mimicking peptide induces glioblastoma stem cell differentiation. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 2282-2292.	2.4	17
369	Epigenetic heterogeneity affects the risk of relapse in children with t(8;21)RUNX1-RUNX1T1-rearranged AML. Leukemia, 2018, 32, 1124-1134.	7.2	17
370	HAIRY CELL LEUKAEMIA WITH T CELL FEATURES. British Journal of Haematology, 1980, 46, 491-492.	2.5	16
371	Persistence of E2A/PBX1 transcripts in t(1;19) childhood acute lymphoblastic leukemia: Correlation with chemotherapy intensity and clinical outcome. Leukemia Research, 1996, 20, 441-443.	0.8	16
372	The effect of cytokines, including IL4, IL7, stem cell factor, insulin-like growth factor on childhood acute lymphoblastic leukemia. Leukemia Research, 1997, 21, 753-761.	0.8	16
373	Gene expression profile unravels significant differences between childhood and adult Ph+ acute lymphoblastic leukemia. Leukemia, 2003, 17, 2234-2237.	7.2	16
374	Synthesis, Cytotoxicity, and Apoptosis Induction in Human Tumor Cells by Geiparvarin Analogues. Chemistry and Biodiversity, 2004, 1, 1265-1280.	2.1	16
375	Differential response of linear and angular psoralens in PUVA-induced apoptosis in HL-60 cells. Photochemical and Photobiological Sciences, 2004, 3, 237-239.	2.9	16
376	Presence of high-ERG expression is an independent unfavorable prognostic marker in MLL-rearranged childhood myeloid leukemia. Blood, 2012, 119, 1086-1087.	1.4	16
377	Glutathione S-transferase homozygous deletions and relapse in childhood acute lymphoblastic leukemia: a novel study design in a large Italian AIEOP cohort. Pharmacogenomics, 2012, 13, 1905-1916.	1.3	16
378	Linking genomic lesions with minimal residual disease improves prognostic stratification in children with T-cell acute lymphoblastic leukaemia. Leukemia Research, 2013, 37, 928-935.	0.8	16

#	Article	IF	Citations
379	Impact of IKZF1 deletions on IKZF1 expression and outcome in Philadelphia chromosome negative childhood BCP-ALL. Reply to "Incidence and biological significance of IKZF1/Ikaros gene deletions in pediatric Philadelphia chromosome negative and Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia". Haematologica, 2013, 98, e164-e165.	3.5	16
380	Synthesis and biological evaluation of imidazo[1,2-a]pyrimidines and imidazo[1,2-a]pyridines as new inhibitors of the Wnt/Î²-catenin signaling. European Journal of Medicinal Chemistry, 2014, 83, 45-56.	5.5	16
381	Patient Satisfaction in Italian Childhood Cancer Survivors: Human Aspects of Treatment as a Key Factor in Patients' Quality of Life. Health and Social Work, 2015, 40, e148-e155.	1.0	16
382	Somatic mutations activating Wiskott-Aldrich syndrome protein concomitant with RAS pathway mutations in juvenile myelomonocytic leukemia patients. Human Mutation, 2018, 39, 579-587.	2.5	16
383	Dual inhibition of PI3K/mTOR signaling in chemoresistant AML primary cells. Advances in Biological Regulation, 2018, 68, 2-9.	2.3	16
384	Adolescent and young adult cancer survivors narrate their stories: Predictive model of their personal growth and their follow-up acceptance. European Journal of Oncology Nursing, 2018, 36, 119-128.	2.1	16
385	SF3B1 homeostasis is critical for survival and therapeutic response in T cell leukemia. Science Advances, 2022, 8, eabj8357.	10.3	16
386	CD4⁺ T regulatory cells are more resistant to DNA damage compared to CD4⁺ T effector cells as revealed by flow cytometric analysis. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2011, 79A, 903-911.	1.5	15
387	Pitavastatin, a new HMG-CoA reductase inhibitor, induces phototoxicity in human keratinocytes NCTC-2544 through the formation of benzophenanthridine-like photoproducts. Archives of Toxicology, 2012, 86, 483-496.	4.2	15
388	Non-Hodgkin lymphoma in children with an associated inherited condition: A retrospective analysis of the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). Pediatric Blood and Cancer, 2015, 62, 1782-1789.	1.5	15
389	Calcineurin and GSK-3 inhibition sensitizes T-cell acute lymphoblastic leukemia cells to apoptosis through X-linked inhibitor of apoptosis protein degradation. Leukemia, 2016, 30, 812-822.	7.2	15
390	2-Alkoxycarbonyl-3-arylamino-5-substituted thiophenes as a novel class of antimicrotubule agents: Design, synthesis, cell growth and tubulin polymerization inhibition. European Journal of Medicinal Chemistry, 2018, 143, 683-698.	5.5	15
391	Motor skill delays in pre-school children with leukemia one year after treatment: Hematopoietic stem cell transplantation therapy as an important risk factor. PLoS ONE, 2017, 12, e0186787.	2.5	15
392	Clinical impact of miR-223 expression in pediatric T-Cell lymphoblastic lymphoma. Oncotarget, 2017, 8, 107886-107898.	1.8	15
393	Treatment reduction in highly selected standard-risk childhood acute lymphoblastic leukemia. The AIEOP ALL-9501 study. Haematologica, 2005, 90, 1186-91.	3.5	15
394	Down-regulation of DLX3 expression in MLL-AF4 childhood lymphoblastic leukemias is mediated by promoter region hypermethylation. Oncology Reports, 2007, 18, 417-23.	2.6	15
395	ABL proteins in Philadelphia-positive acute leukaemias and chronic myelogenous leukaemia blast crises. British Journal of Haematology, 1990, 76, 39-44.	2.5	14
396	Value of cytogenetics in the differential diagnosis of the small round cell tumors of childhood. Medical and Pediatric Oncology, 1992, 20, 130-135.	1.0	14

#	Article	IF	Citations
397	Molecular characterization of a new recombination of the SIL/TAL-1 locus in a child with T-cell acute lymphoblastic leukaemia. British Journal of Haematology, 2002, 118, 1011-1018.	2.5	14
398	T cells stimulated by CD40L positive leukemic blasts-pulsed dendritic cells meet optimal functional requirements for adoptive T-cell therapy. Leukemia, 2006, 20, 2015-2024.	7.2	14
399	Diazoniapolycyclic Ions Inhibit the Activity of Topoisomeraseâ€…I and the Growth of Certain Tumor Cell Lines. ChemMedChem, 2008, 3, 1671-1676.	3.2	14
400	Identification of the NUP98-PHF23 fusion gene in pediatric cytogenetically normal acute myeloid leukemia by whole-transcriptome sequencing. Journal of Hematology and Oncology, 2015, 8, 69.	17.0	14
401	Cognitive evoked potentials and neural networks are abnormal in children with sickle cell disease and not related to the degree of anaemia, pain and silent infarcts. British Journal of Haematology, 2015, 169, 597-600.	2.5	14
402	New more polar symmetrical bipyridinic compounds: new strategy for the inhibition of choline kinase Î±1. Future Medicinal Chemistry, 2015, 7, 417-436.	2.3	14
403	Profiling B cell chronic lymphocytic leukemia by reverse phase protein array: Focus on apoptotic proteins. Journal of Leukocyte Biology, 2016, 100, 1061-1070.	3.3	14
404	Psychopathological Aspects in Childhood Hematopoietic Stem Cell Transplantation (HSCT): The Perception of Parents and Adolescents. Frontiers in Psychology, 2017, 8, 272.	2.1	14
405	Results of a multicenter universal newborn screening program for sickle cell disease in Italy: A call to action. Pediatric Blood and Cancer, 2019, 66, e27657.	1.5	14
406	Core Binding Factor Acute Myeloid Leukemia In Pediatric Patients Enrolled In The AIEOP AML 2002/01 Trial: The Impact Of Minimal Residual Disease On Patient Outcome. Blood, 2013, 122, 3884-3884.	1.4	14
407	mTOR inhibition downregulates glucose-6-phosphate dehydrogenase and induces ROS-dependent death in T-cell acute lymphoblastic leukemia cells. Redox Biology, 2022, 51, 102268.	9.0	14
408	The effect of the cyclin-dependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity. Haematologica, 2009, 94, 944-955.	3.5	13
409	Frequent and sex-biased deletion of SLX4IP by illegitimate V(D)J-mediated recombination in childhood acute lymphoblastic leukemia. Human Molecular Genetics, 2014, 23, 590-601.	2.9	13
410	The Novel Antitubulin Agent TR-764 Strongly Reduces Tumor Vasculature and Inhibits HIF-1Î± Activation. Scientific Reports, 2016, 6, 27886.	3.3	13
411	Synthesis, structure-activity relationships and biological evaluation ofÂ7-phenyl-pyrroloquinolinone 3-amide derivatives as potent antimitotic agents. European Journal of Medicinal Chemistry, 2017, 127, 643-660.	5.5	13
412	Prognostic value of minimal residual disease measured by flow-cytometry in two cohorts of infants with acute lymphoblastic leukemia treated according to either MLL-Baby or Interfant protocols. Leukemia, 2020, 34, 3042-3046.	7.2	13
413	Frequent clonal loss of heterozygosity (LOH) in the chromosomal region 1p32 occurs in childhood T cell acute lymphoblastic leukemia (T-ALL) carrying rearrangements of the TAL1 gene. Leukemia, 1997, 11, 359-363.	7.2	12
414	Genotypes of the glutathione S-transferase superfamily do not correlate with outcome of childhood acute lymphoblastic leukemia. Leukemia, 2003, 17, 981-983.	7.2	12

#	Article	IF	Citations
415	Independent clones at separable stages of differentiation, bearing different GATA1 mutations, in the same TMD patient with Down syndrome. Blood, 2005, 106, 1887-1888.	1.4	12
416	New data on robustness of gene expression signatures in leukemia: comparison of three distinct total RNA preparation procedures. BMC Genomics, 2007, 8, 188.	2.8	12
417	Isolation and Expansion of Regionally Defined Human Glioblastoma Cells In Vitro. Current Protocols in Stem Cell Biology, 2011, 17, Unit 3.4.	3.0	12
418	Whole transcriptome sequencing of a paediatric case of de novo acute myeloid leukaemia with del(5q) reveals <scp>RUNX</scp>1â€<scp>USP</scp>42 and <scp>PRDM</scp>16â€<scp>SKI</scp> fusion transcripts. British Journal of Haematology, 2014, 166, 449-452.	2.5	12
419	Hematopoietic stem cell transplantation for isolated extramedullary relapse of acute lymphoblastic leukemia in children. Bone Marrow Transplantation, 2019, 54, 275-283.	2.4	12
420	Impact of Minimal Residual Disease (MRD) on Prognosis in Children with Acute Lymphoblastic Leukemia (ALL) According to WBC Count, Age and TEL/AML1 Status at Diagnosis. Results of the AIEOP-BFM ALL 2000 Study.. Blood, 2007, 110, 544-544.	1.4	12
421	Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition. International Journal of Molecular Medicine, 2004, 14, 373-82.	4.0	12
422	Outcome after cessation of therapy in childhood acute lymphoblastic leukaemia. European Journal of Cancer, 1993, 29, 1839-1843.	2.8	11
423	Is the deletion of the short arm of chromosome 1 a prognostic factor in pediatric peripheral primitive neuroepithelioma (PNET)?. , 1996, 26, 143-144.		11
424	Association of cytogenetic abnormalities with detection of BCRâ€ABL fusion transcripts in children with Tâ€lineage lymphoproliferative diseases (Tâ€ALL and Tâ€NHL). Pediatric Blood and Cancer, 2004, 42, 278-280.	1.5	11
425	Reply to van der Sluijs-Gelling et al. Leukemia, 2005, 19, 2351-2352.	7.2	11
426	Diagnosis and genetic subtypes of leukemia combining gene expression and flow cytometry. Blood Cells, Molecules, and Diseases, 2007, 39, 164-168.	1.4	11
427	DNA methyltransferase 3a hot-spot locus is not mutated in pediatric patients affected by acute myeloid or T-cell acute lymphoblastic leukemia: an Italian study. Haematologica, 2011, 96, 1886-1887.	3.5	11
428	Screening of novel genetic aberrations in pediatric acute myeloid leukemia: a report from the AIEOP AML-2002 study group. Blood, 2012, 120, 3860-3862.	1.4	11
429	Psychosocial life achievements in adults even if they received prophylactic cranial irradiation for acute lymphoblastic leukemia during childhood. Leukemia and Lymphoma, 2013, 54, 315-320.	1.3	11
430	Understanding the Interplay between Expression, Mutation and Activity of ALK Receptor in Rhabdomyosarcoma Cells for Clinical Application of Small-Molecule Inhibitors. PLoS ONE, 2015, 10, e0132330.	2.5	11
431	Targeting BAG-1: A novel strategy to increase drug efficacy in acute myeloid leukemia. Experimental Hematology, 2015, 43, 180-190.e6.	0.4	11
432	Three novel fusion transcripts of the paired box 5 gene in B-cell precursor acute lymphoblastic leukemia. Haematologica, 2015, 100, e14-e17.	3.5	11

#	Article	IF	Citations
433	Macrolide antibiotics exert antileukemic effects by modulating the autophagic flux through inhibition of hERG1 potassium channels. Blood Cancer Journal, 2016, 6, e423-e423.	6.2	11
434	DNA variants in DHFR gene and response to treatment in children with childhood B ALL: revisited in AIEOP-BFM protocol. Pharmacogenomics, 2018, 19, 105-112.	1.3	11
435	A high definition picture of key genes and pathways mutated in pediatric follicular lymphoma. Haematologica, 2019, 104, e406-e409.	3.5	11
436	Incidence and Clinical Relevance of TEL/AML1 Fusion Genes in Children With Acute Lymphoblastic Leukemia Enrolled in the German and Italian Multicenter Therapy Trials. Blood, 1997, 90, 571-577.	1.4	11
437	Active and late rosette-forming cells: Immunological and cytochemical characterization. Cellular Immunology, 1981, 64, 227-234.	3.0	10
438	Altered mRNA expression of PAX5 is a common event in acute lymphoblastic leukaemia. British Journal of Haematology, 2009, 146, 686-689.	2.5	10
439	Amplified segment in the â€˜Down Syndrome critical regionâ€™ on HSA21 shared between Down syndrome and euploid AML-M0 excludes RUNX1, ERG and ETS2. British Journal of Haematology, 2012, 157, 197-200.	2.5	10
440	Expression and Distribution of the Adrenomedullin System in Newborn Human Thymus. PLoS ONE, 2014, 9, e97592.	2.5	10
441	Flow diagnostics essential code: A simple and brief format for the summary of leukemia phenotyping. , 2014, 86, 288-291.		10
442	A Case of Tâ€cell Acute Lymphoblastic Leukemia Relapsed As Myeloid Acute Leukemia. Pediatric Blood and Cancer, 2016, 63, 1660-1663.	1.5	10
443	NPM-ALK expression levels identify two distinct subtypes of paediatric anaplastic large cell lymphoma. Leukemia, 2017, 31, 498-501.	7.2	10
444	Quality of Life and Psychopathology in Adults Who Underwent Hematopoietic Stem Cell Transplantation (HSCT) in Childhood: A Qualitative and Quantitative Analysis. Frontiers in Psychology, 2017, 8, 1316.	2.1	10
445	Primary mediastinal large Bâ€cell lymphoma: Outcome of a series of pediatric patients treated with highâ€dose methotrexate and cytarabine plus antiâ€CD20. Pediatric Blood and Cancer, 2018, 65, e26855.	1.5	10
446	Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia. JNCI Cancer Spectrum, 2018, 2, pky069.	2.9	10
447	SYK Targeting Represents a Potential Therapeutic Option for Relapsed Resistant Pediatric ETV6-RUNX1 B-Acute Lymphoblastic Leukemia Patients. International Journal of Molecular Sciences, 2019, 20, 6175.	4.1	10
448	<scp>CD56</scp>, <scp>HLAâ€DR,</scp> and <scp>CD45</scp> recognize a subtype of childhood <scp>AML</scp> harboring <scp>CBFA2T3â€GLIS2</scp> fusion transcript. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2021, 99, 844-850.	1.5	10
449	The Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Sub-Classification of Leukemia: Final Report on 3252 Cases from the International MILE Study Group. Blood, 2008, 112, 753-753.	1.4	10
450	Differences in circulating microRNA signature in Praderâ€“Willi syndrome and non-syndromic obesity. Endocrine Connections, 2018, 7, 1262-1274.	1.9	10

#	Article	IF	Citations
451	Recommended reporting format for flow cytometry diagnosis of acute leukemia. Haematologica, 2004, 89, 594-8.	3.5	10
452	Cytokeratins patterns in childhood primary liver tumors. International Journal of Clinical and Laboratory Research, 1993, 23, 225-227.	1.0	9
453	Distribution ofTP53 mutations among acute leukemias withMLL rearrangements. , 1996, 15, 48-53.		9
454	p16INK4A gene homozygous deletions in human acute leukaemias with alterations of chromosome 9. British Journal of Haematology, 1996, 93, 632-636.	2.5	9
455	Fluorescence in situ hybridization improves cytogenetic results in the analysis of hepatoblastoma. Cancer Genetics and Cytogenetics, 2002, 134, 18-20.	1.0	9
456	Linking Hepatic Transcriptional Changes to Highâ€“Fat Diet Induced Physiology for Diabetes-Prone and Obese-Resistant Mice. Cell Cycle, 2007, 6, 1631-1638.	2.6	9
457	Heterogeneity of TdT +, HLAâ€Ð R + acute leukaemia: Immunological, immunocytochemical and clinical evidence of lymphoid and myeloid origin. European Journal of Haematology, 1987, 38, 111-116.	2.2	9
458	Pyrrolotetrazinones deazaanalogues of temozolomide induce apoptosis in Jurkat cell line: involvement of tubulin polymerization inhibition. Cancer Chemotherapy and Pharmacology, 2009, 64, 1235-1251.	2.3	9
459	Low prevalence of IDH1 gene mutation in childhood AML in Italy. Leukemia, 2011, 25, 173-174.	7.2	9
460	Proteomic Alterations in Response to Hypoxia Inducible Factor 2Î± in Normoxic Neuroblastoma Cells. Journal of Proteome Research, 2016, 15, 3643-3655.	3.7	9
461	Longitudinal evaluation of cerebral white matter hyperintensities lesion volume in children with sickle cell disease. British Journal of Haematology, 2017, 176, 485-487.	2.5	9
462	Selective Difficulties in Lexical Retrieval and Nonverbal Executive Functioning in Children With HbSS Sickle Cell Disease. Journal of Pediatric Psychology, 2018, 43, 666-677.	2.1	9
463	Genetic characterization and therapeutic targeting of MYCâ€rearranged T cell acute lymphoblastic leukaemia. British Journal of Haematology, 2019, 185, 169-174.	2.5	9
464	Results of the AIEOP AML 2002/01 Study for Treatment of Children with Acute Myeloid Leukemia.. Blood, 2009, 114, 17-17.	1.4	9
465	Philadelphia-Like Signature In Childhood Acute Lymphoblastic Leukemia: The AIEOP Experience. Blood, 2013, 122, 353-353.	1.4	9
466	Study of cytochemical markers ACP and ANAE in childhood lymphoma and leukaemia. British Journal of Cancer, 1980, 41, 835-838.	6.4	8
467	Karyotype evolution in a patient with biphenotypic neonatal leukemia. Cancer Genetics and Cytogenetics, 1992, 62, 124-129.	1.0	8
468	The c-kit Receptor and Its Ligand Stem Cell Factor in Childhood Malignant Lymphoid Precursors. Journal of Interferon and Cytokine Research, 1999, 19, 981-987.	1.2	8

#	Article	IF	Citations
469	Intron 2 [IVS2, T-C +4] HFE gene mutation associated with S65C causes alternative RNA splicing and is responsible for iron overload. Hepatology Research, 2005, 33, 57-60.	3.4	8
470	Are genotypes of glutathione S-transferase superfamily a risk factor for childhood acute lymphoblastic leukemia? Results of an Italian caseâ€“control study. Leukemia, 2007, 21, 1122-1124.	7.2	8
471	Identification of immunophenotypic signatures by clustering analysis in pediatric patients with Philadelphia chromosomeâ€positive acute lymphoblastic leukemia. American Journal of Hematology, 2010, 85, 138-141.	4.1	8
472	<scp>l</scp>-Proline as a modulator of ectodermal differentiation in ES cells. Focus on â€œ<scp>l</scp>-Proline induces differentiation of ES cells: a novel role for an amino acid in the regulation of pluripotent cells in culture. American Journal of Physiology - Cell Physiology, 2010, 298, C979-C981.	4.6	8
473	Ex vivo-expanded bone marrow CD34+ for acute myocardial infarction treatment: in vitro and in vivo studies. Cytotherapy, 2011, 13, 1140-1152.	0.7	8
474	Interleukinâ€22 in the diagnosis of active chronic graftâ€versusâ€host disease in paediatric patients. British Journal of Haematology, 2015, 168, 142-145.	2.5	8
475	A threeâ€mi<scp>RNA</scp>â€based expression signature at diagnosis can predict occurrence of relapse in children with t(8;21) <scp>RUNX</scp>1â€<scp>RUNX</scp>1T1 acute myeloid leukaemia. British Journal of Haematology, 2018, 183, 298-301.	2.5	8
476	Course of antiâ€<scp>ALK</scp> antibody titres during chemotherapy in children with anaplastic large cell lymphoma. British Journal of Haematology, 2018, 182, 733-735.	2.5	8
477	Cerebrospinal fluid analysis by 8-color flow cytometry in children with acute lymphoblastic leukemia. Leukemia and Lymphoma, 2019, 60, 2825-2828.	1.3	8
478	Acute Lymphoblastic Leukemia in Children with Down Syndrome: A Report From the Ponte Di Legno Study Group,. Blood, 2011, 118, 3579-3579.	1.4	8
479	c-kit Is Expressed in Soft Tissue Sarcoma of Neuroectodermic Origin and Its Ligand Prevents Apoptosis of Neoplastic Cells. Blood, 1998, 91, 2397-2405.	1.4	8
480	Children with TEL/AML1-Positive Acute Lymphoblastic Leukemia (ALL) and Favorable Presenting Features May Benefit from the Use of Vincristine-Dexamethasone (VCR-DXM) Pulses on Top of Antimetabolite-Based Continuation Therapy.. Blood, 2005, 106, 9-9.	1.4	8
481	Two consecutive immunophenotypic switches in a child with MLL-rearranged acute lymphoblastic leukemia. Haematologica, 2006, 91, ECR09.	3.5	8
482	Molecular characterization of Phâ€²+ hybrid acute leukemia. Leukemia Research, 1989, 13, 1061-1067.	0.8	7
483	Rhabdomyosarcoma with Primary Osteolytic Lesions Simulating Non-Hodgkin's Lymphoma. Pediatric Hematology and Oncology, 1991, 8, 159-164.	0.8	7
484	Clinical features of childhood acute myeloid leukaemia with specific gene rearrangements. Leukemia, 2004, 18, 1427-1429.	7.2	7
485	Hemiasterlin analogues incorporating an aromatic, and heterocyclic type C-terminus: design, synthesis and biological evaluation. Molecular Diversity, 2014, 18, 357-373.	3.9	7
486	ALK Kinase Domain Mutations in Primary Anaplastic Large Cell Lymphoma: Consequences on NPM-ALK Activity and Sensitivity to Tyrosine Kinase Inhibitors. PLoS ONE, 2015, 10, e0121378.	2.5	7

#	Article	IF	Citations
487	Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALL. Blood, 2017, 130, 2146-2149.	1.4	7
488	Haploidentical stem cell transplantation cures autoimmune hepatitis and cerebrovascular disease in a patient with sickle cell disease. Bone Marrow Transplantation, 2018, 53, 644-646.	2.4	7
489	GIMEMA-AIEOP AIDA Protocols for the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL) In Children: Analysis of 247 Patients Enrolled In Two Sequential Italian Multicenter Trials. Blood, 2010, 116, 871-871.	1.4	7
490	D cells with cytotoxic activity in acute lymphoblastic leukemia. Clinical Immunology and Immunopathology, 1980, 16, 238-244.	2.0	6
491	Non-T, non-B childhood acute lymphoblastic leukemia. Correlation between cytochemical markers and first complete remission. Cancer, 1984, 54, 981-985.	4.1	6
492	17q21â€“qter trisomy is an indicator of poor prognosis in acute myelogenous leukemia. Cancer Genetics and Cytogenetics, 2001, 124, 12-15.	1.0	6
493	Acute Leukemia Subclassification: A Marker Protein Expression Perspective. Hematology, 2004, 9, 165-170.	1.5	6
494	Down-regulation of DLX3 expression in MLL-AF4 childhood lymphoblastic leukemias is mediated by promoter region hypermethylation. Oncology Reports, 2007, , .	2.6	6
495	ICER Evokes Dusp1-p38 Pathway Enhancing Chemotherapy Sensitivity in Myeloid Leukemia. Clinical Cancer Research, 2011, 17, 742-752.	7.0	6
496	Gain-of-function mutations in interleukin-7 receptor-Î± (IL7R) in childhood acute lymphoblastic leukemias. Journal of Experimental Medicine, 2011, 208, 1333-1333.	8.5	6
497	Gene expression signatures of pediatric myelodysplastic syndromes are associated with risk of evolution into acute myeloid leukemia. Leukemia, 2012, 26, 1717-1719.	7.2	6
498	Haploidentical TCR A/B and B-cell depleted hematopoietic SCT in pediatric SAA and aspergillosis. Bone Marrow Transplantation, 2014, 49, 847-849.	2.4	6
499	Association between a combination of single nucleotide polymorphisms and large vessel cerebral vasculopathy in African children with sickle cell disease. Blood Cells, Molecules, and Diseases, 2016, 61, 1-3.	1.4	6
500	Attachment orientations and psychological adjustment of parents of children with cancer: A matched-group comparison. Journal of Psychosocial Oncology, 2017, 35, 726-740.	1.2	6
501	Reduced Intensity Delayed Intensification in Standard-Risk Patients Defined By Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia: Results of an International Randomized Trial in 1164 Patients (Trial AIEOP-BFM ALL 2000). Blood, 2016, 128, 4-4.	1.4	6
502	Evolution of Sub-Clones with KRAS Mutations In Pediatric Patients with MLL-AF4 Rearrangements. Blood, 2011, 118, 2454-2454.	1.4	6
503	Can primary cancer of the liver in western countries be prevented? Pediatric point of view. Medical and Pediatric Oncology, 1990, 18, 57-60.	1.0	5
504	Immunophenotype signature as a tool to define prognostic subgroups in childhood acute myeloid leukemia. Leukemia, 2006, 20, 888-891.	7.2	5

#	Article	IF	Citations
505	Acute differentiated dendritic cell leukemia: a variant form of pediatric acute myeloid leukemia with MLL translocation. Leukemia, 2007, 21, 360-362.	7.2	5
506	mll ortholog containing functional domains of human MLL is expressed throughout the zebrafish lifespan and in haematopoietic tissues. British Journal of Haematology, 2011, 152, 307-321.	2.5	5
507	Flow diagnostics essential (FDE) code: A simple and brief format for the summary of leukemia phenotyping. , 2013, , n/a-n/a.		5
508	Expression of the immunoglobulin superfamily cell membrane adhesion molecule Cd146 in acute leukemia. Cytometry Part B - Clinical Cytometry, 2016, 90, 247-256.	1.5	5
509	The hematopoietic stem cell marker VNN2 is associated with chemoresistance in pediatric B-cell precursor ALL. Blood Advances, 2020, 4, 4052-4064.	5.2	5
510	RAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemia. Oncogene, 2021, 40, 746-762.	5.9	5
511	Adaptive Functioning of Preschooler Children with Leukemia Post 1 Year of Therapies Compared with Sane Peers. British Journal of Education Society & Behavioural Science, 2016, 18, 1-15.	0.1	5
512	Peculiar allelotype associated with susceptibility to neuroblastoma. , 1996, 17, 60-63.		4
513	Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition. International Journal of Molecular Medicine, 2004, 14, 373.	4.0	4
514	Comparative sequence analysis of incomplete DJH and TCR gene rearrangements in children with relapses of T-ALL. Leukemia, 2005, 19, 1687-1689.	7.2	4
515	Immunocytochemical evidence of commonâ€ALL antigen in nullâ€ALL. Scandinavian Journal of Haematology, 1985, 35, 536-542.	0.0	4
516	Evaluation of Technical Issues in a Pilot Multicenter Newborn Screening Program for Sickle Cell Disease. International Journal of Neonatal Screening, 2019, 5, 2.	3.2	4
517	The altered transcriptome of pediatric myelodysplastic syndrome revealed by RNA sequencing. Journal of Hematology and Oncology, 2020, 13, 135.	17.0	4
518	Digital-Droplet PCR, an Accurate Method for IG/TR PCR-MRD Stratification in Childhood Acute Lymphoblastic Leukemia. Blood, 2018, 132, 1544-1544.	1.4	4
519	High Dose Methotrexate (HD MTX at 2 gr/sqm x 4) Associated to Extended Intrathecal (IT) Chemotherapy Is Effective for Prevention of Central Nervous System (CNS) Relapse in Childhood ALL Treated with BFM Systemic Therapy.. Blood, 2005, 106, 10-10.	1.4	4
520	Treatment Intensification of Traditional BFM Therapy with 3 Chemotherapy Blocks and Double Delayed Intensification (Protocol II) Improves Outcome in Infants with High Risk (HR) Acute Lymphoblastic Leukemia (ALL): Results of Two Consecutive AIEOP Studies.. Blood, 2005, 106, 871-871.	1.4	4
521	The Strong Prognostic Effect of Concurrent Deletions of IKZF1 and PAX5, CDKN2A, CDKN2B or PAR1 in the Absence of ERG Deletions (IKZF1plus) in Pediatric Acute Lymphoblastic Leukemia Strongly Depends on Minimal Residual Disease Burden after Induction Treatment. Blood, 2014, 124, 131-131.	1.4	4
522	Genomic Landscape of Pediatric Mixed Phenotype Acute Leukemia. Blood, 2016, 128, 454-454.	1.4	4

#	Article	IF	Citations
523	IKZF1 and 22q11.22 Deletions and PDGFRA Gains Are Associated with Poor Outcome in Down Syndrome Acute Lymphoblastic Leukemia. Blood, 2012, 120, 289-289.	1.4	4
524	Loss of PTEN in Pediatric T-Cell Acute Lymphoblastic Leukemia Patients: Proteomic and Molecular Characterization. Blood, 2014, 124, 2408-2408.	1.4	4
525	Poor Prognosis in Children with ABL-Class Fusion Positive B-Cell Acute Lymphoblastic Leukemia Treated According to AIEOP-BFM Protocols. Blood, 2019, 134, 1351-1351.	1.4	4
526	N-Acetyl-Î²-D-Glucosaminidase Activity in T Chronic Lymphocytic Leukaemia. Acta Haematologica, 1981, 66, 69-70.	1.4	3
527	Non-Radiolabelled PCR Consensus Primers and Automatic Sequencing Enable Rapid Identification of Tumor-Specific V_HCDR3 in Aggressive B-Cell Malignancies. Leukemia and Lymphoma, 2003, 44, 1597-1601.	1.3	3
528	Bone marrow ectopic expression of a non-coding RNA in childhood T-cell acute lymphoblastic leukemia with a novel t(2;11)(q11.2;p15.1) translocation. Molecular Cancer, 2008, 7, 80.	19.2	3
529	Longâ€term results of AIEOPâ€8805 protocol for acute Bâ€cell lymphoblastic leukemia of childhood. Pediatric Blood and Cancer, 2011, 56, 544-550.	1.5	3
530	Nextâ€generation sequencing of PTEN mutations for monitoring minimal residual disease in Tâ€cell acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2020, 67, e28025.	1.5	3
531	BAG1 downâ€regulation increases chemoâ€sensitivity of acute lymphoblastic leukaemia cells. Journal of Cellular and Molecular Medicine, 2021, 25, 9060-9065.	3.6	3
532	An International Multi-Center Study To Define the Application of Microarrays in the Diagnosis and Subclassification of Leukemia (MILE Study): Interim Analysis Based on 1,889 Patients Achieves 95.4% Prediction Accuracy.. Blood, 2006, 108, 103-103.	1.4	3
533	Inhibition of NOTCH1 Signaling and Glucocorticoid Therapy in T-ALL. Blood, 2008, 112, 298-298.	1.4	3
534	Time Point-Dependent Concordance of Flow Cytometry and RQ-PCR in the MRD Detection in Childhood ALL: The Experience of the AIEOP-BFM- ALL MRD Study Group. Blood, 2008, 112, 700-700.	1.4	3
535	NUP98 Fusion Proteins Are Recurrent Aberrancies in Childhood Acute Myeloid Leukemia: A Report from the AIEOP AML-2001-02 Study Group. Blood, 2014, 124, 1025-1025.	1.4	3
536	Clonal Evolution and Lack of BCR-ABL1 Mutations in Pediatric Ph+ ALL Patients Resistant/Refractory to Imatinib Treatment. Blood, 2015, 126, 2622-2622.	1.4	3
537	Autosomal dominant macrothrombocytopenia with ineffective thrombopoiesis. Haematologica, 2002, 87, ELT27.	3.5	3
538	Effects of exposure to extremely low frequency electro-magnetic fields on circadian rhythms and distribution of some leukocyte differentiation antigens in dairy cows. Biomedical and Environmental Sciences, 2007, 20, 164-70.	0.2	3
539	FLT3-ITD in Children with Early T-cell Precursor (ETP) Acute Lymphoblastic Leukemia: Incidence and Potential Target for Monitoring Minimal Residual Disease (MRD). Cancers, 2022, 14, 2475.	3.7	3
540	Childhood liver tumour tissue storage programme: A siop liver tumour study initiative. Medical and Pediatric Oncology, 1994, 22, 425-427.	1.0	2

#	Article	IF	Citations
541	Symmetrical Î±-bromoacryloylamido diaryldienone derivatives as a novel series of antiproliferative agents. Design, synthesis and biological evaluation. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2733-2739.	2.2	2
542	Non-medical applications of non-invasive prenatal diagnosis: Ethical issues. Forensic Science International: Genetics Supplement Series, 2011, 3, e554-e555.	0.3	2
543	TNF-Î± SNP rs1800629 and risk of relapse in childhood acute lymphoblastic leukemia: relation to immunophenotype. Pharmacogenomics, 2014, 15, 619-627.	1.3	2
544	Ruxolitinib as a Novel Therapeutic Option for Poor Prognosis T-LBL Pediatric Patients. Cancers, 2021, 13, 3724.	3.7	2
545	Prognostic Impact of Minimal Residual Disease (MRD) in Children Is Different in B or T Lineage Acute Lymphoblastic Leukemia: Results of Trial AIEOP-BFM ALL 2000.. Blood, 2007, 110, 1425-1425.	1.4	2
546	Expression and Role of hERG1 Channels in Pediatric Acute Lymphoblastic Leukemias: Shortcoming of Drug Resistance by hERG1 Channel Inhibitors in Stoma-Supported Leukaemia Cell Cultures In Vitro.. Blood, 2007, 110, 724-724.	1.4	2
547	Collaboration between Activating Mutations in JAK2 and Trisomy 21 in the Acute Lymphoblastic Leukemias of Down Syndrome (DS).. Blood, 2007, 110, LB6-LB6.	1.4	2
548	CRLF2 over-Expression Is a Poor Prognostic Marker in Children with High Risk T-Cell Acute Lymphoblastic Leukemia. Blood, 2014, 124, 1071-1071.	1.4	2
549	The Genomic Landscape of Childhood and Adult Acute Erythroid Leukemia. Blood, 2016, 128, 39-39.	1.4	2
550	Acute Leukemia of Ambiguous Lineage: A Comprehensive Survival Analysis Enables Designing New Treatment Strategies. Blood, 2016, 128, 584-584.	1.4	2
551	Mutational Loss of PTEN Induces Resistance to NOTCH1 Inhibition in T-ALL.. Blood, 2007, 110, 5-5.	1.4	2
552	Results of the AIEOP-BFM ALL 2000 Study for Childhood Acute Lymphoblastic Leukemia IN AIEOP High Risk Patients.. Blood, 2009, 114, 319-319.	1.4	2
553	Favorable Outcome of Children with Acute Megakaryoblastic Leukemia Treated with the AIEOP AML 2002/01 Protocol. Blood, 2012, 120, 3586-3586.	1.4	2
554	Late relapse of childhood acute lymphoblastic leukemia and pcr-monitoring of minimal residual disease: how much time can elapse between "molecular" and clinical relapse?. Haematologica, 2002, 87, ELT19.	3.5	2
555	Validation by RQ-PCR and flow cytometry of alpha-defensin1-3 (DEFA1-3) overexpression in relapsed and refractory acute lymphoblastic leukemia. Oncology Reports, 2006, 15, 341-6.	2.6	2
556	Li-Fraumeni syndrome: a case report from Italy. British Journal of Cancer, 1990, 61, 341-341.	6.4	1
557	Significance of Serial Biopsies After Renal Allograft in Children. Transplantation Proceedings, 1998, 30, 1321-1323.	0.6	1
558	Genomic Landscape of Acute Erythroid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S26-S27.	0.4	1

#	Article	IF	Citations
559	Acute Lymphoid Leukaemias (ALL) and Minimal Residual Disease in ALL. , 0, , 89-104.		1
560	Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia and Lymphoma, 2018, 59, 1268-1270.	1.3	1
561	A mixed-methods study of the disease experience in hematopoietic stem cell transplantation survivors: the contribution of text analysis. Journal of Psychosocial Oncology, 2020, 38, 728-745.	1.2	1
562	Genetic and Epigenetic Characterization of a Discordant KMT2A/AFF1-Rearranged Infant Monozygotic Twin Pair. International Journal of Molecular Sciences, 2021, 22, 9740.	4.1	1
563	Non-Radiolabelled PCR Consensus Primers and Automatic Sequencing Enable Rapid Identification of Tumor-Specific V H CDR3 in Aggressive B-Cell Malignancies. Leukemia and Lymphoma, 2003, 44, 1597-1601.	1.3	1
564	High Clonal Evolution Rate in Relapsing Infant ALL Patients.. Blood, 2004, 104, 164-164.	1.4	1
565	c-Met Oncogene Enhances Fas-Mediated Apoptosis in B-ALL t(12;21) Cells.. Blood, 2005, 106, 858-858.	1.4	1
566	Prevalence and Clinical Correlates of JAK2 Mutations in Pediatric Down Syndrome Acute Lymphoblastic Leukemia.. Blood, 2008, 112, 1506-1506.	1.4	1
567	Reverse Phase Protein Assay (RPPA) Defines Specific Patterns in Childhood Acute Lymphoblastic Leukemia (ALL). Blood, 2008, 112, 2510-2510.	1.4	1
568	Gene Expression Profiling in Down Syndrome Acute Lymphoblastic Leukemia Identifies Distinct Profiles Associated with CRLF2 Expression Status.. Blood, 2009, 114, 2389-2389.	1.4	1
569	Expression of Annexin 2 in Pediatric B-Acute Lymphoblastic Leukemia: A Marker of Aggressiveness and A Potential Therapeutic Target.. Blood, 2009, 114, 2605-2605.	1.4	1
570	Overcoming Chemotherapy Resistance in Childhood Acute Lymphoblastic Leukemia by Targeting Ion Channels.. Blood, 2009, 114, 3085-3085.	1.4	1
571	Poor Prognosis for IKZF1 Intra-Gene Deletions in Pediatric Phâ^' B-Cell Precursor Acute Lymphoblastic Leukemia,. Blood, 2011, 118, 3518-3518.	1.4	1
572	FLT3-ITD As a Target for Minimal Residual Disease Monitoring in Early T-Cell Precursor (ETP) Acute Lymphoblastic Leukemia. Blood, 2014, 124, 1073-1073.	1.4	1
573	FOXM1 Is Overexpressed in B-Acute Lymphoblastic Leukemia (B-All) and Its Inhibition Sensitizes B-All Cells to Chemotherapeutic Drugs. Blood, 2014, 124, 2245-2245.	1.4	1
574	Outcome of Early T-Cell Precursor Acute Lymphoblastic Leukemia in AIEOP Patients Treated with the AIEOP-BFM ALL 2000 Study. Blood, 2014, 124, 3780-3780.	1.4	1
575	Antithrombin Plasma Levels and Fibtem Determination in Children with Acute Lymphoblastic Leukemia Undergoing Asparaginase Treatment. Blood, 2014, 124, 5246-5246.	1.4	1
576	Validation of MRD Quantification By Flow Cytometry for Pediatric BCP ALL Relapsed Patients Treated on the Intreall Protocol. Blood, 2015, 126, 1414-1414.	1.4	1

#	Article	IF	Citations
577	Dna Methylation Is Linked to a Specific Cell-Adhesion Program in Relapsed Pediatric t(8;21)(q22;q22)RUNX1-RUNX1T1 Patients. Blood, 2016, 128, 1524-1524.	1.4	1
578	Expression of Myeloid Markers Lacks Prognostic Impact in Children Treated for Acute Lymphoblastic Leukemia: Italian Experience in AIEOP-ALL 88-91 Studies. Blood, 1998, 92, 795-801.	1.4	1
579	Early Evaluation of Bone Marrow Minimal Residual Disease by Flowcytometry on Day 15 Is Feasible on a Multicenter Basis and Bears Strong Prognostic Value in Childhood Acute Lymphoblastic Leukemia. The AIEOP-BFM Experience.. Blood, 2007, 110, 1423-1423.	1.4	1
580	Long-Term Outcome of Children with Acute Myeloid Leukemia in First Remission Given Allogeneic HSCT from a Matched Family Donor After a Conditioning Regimen Comprising Busulfan, Cyclophosphamide and Melphalan.. Blood, 2009, 114, 2288-2288.	1.4	1
581	af9 Regulates gata2 Expression During Early Hemangioblast Specification and Vascular Pattern Formation In Zebrafish.. Blood, 2010, 116, 2600-2600.	1.4	1
582	MiR-34b Promoter Methylation and Regulation of CREB Expression In Myeloid Transformation. Blood, 2010, 116, 538-538.	1.4	1
583	Specific Circulating Microvesicles (cMVs) Populations in Paediatric ALL. Blood, 2011, 118, 933-933.	1.4	1
584	Zebrafish Ortholog of Human DOT1L Regulates Primitive and Transient Definitive Hematopoiesis and Controls hoxa9 and meis1 Expression. Blood, 2012, 120, 849-849.	1.4	1
585	Novel Chimeric Transcripts Involving PAX5 in B-Cell Precursor ALL. Blood, 2013, 122, 1367-1367.	1.4	1
586	Subunit a of Coagulation Factor XIII As a New Biomarker in Childhood Acute Lymphoblastic Leukemia?. Blood, 2014, 124, 5346-5346.	1.4	1
587	Microrna-150 Regulates STAT5b Levels in Juvenile Myelomonocytic Leukemia (JMML). Blood, 2015, 126, 2851-2851.	1.4	1
588	Children with Thalassemia Major Display Abnormal Renal Tubular Function. Blood, 2016, 128, 3628-3628.	1.4	1
589	Features of Avascular Osteonecrosis in Children Treated for Acute Lymphoblastic Leukaemia: Experience in a Single Center. Blood, 2016, 128, 5158-5158.	1.4	1
590	Macrolide Antibiotics By Modulating the Autophagic Flux Exert an Antileukemic Effect through the Involvement of hERG1 Potassium Channel. Blood, 2016, 128, 3953-3953.	1.4	1
591	Transient Switch to Myeloid Lineage in Acute Lymphoblastic Leukemia during Induction Therapy: The Role of CD371 Expression and Implication for Minimal Residual Disease Detection. Blood, 2019, 134, 377-377.	1.4	1
592	Leukemia blast cell identification. Wiley Interdisciplinary Reviews: Data Mining and Knowledge Discovery, 2015, 5, 74-85.	6.8	0
593	Feasibility of Multicentric Assessment of MRD in All by Flow-Cytometry: Standardization and Experience of the I-BFM-ALL FCM-MRD Study Group.. Blood, 2004, 104, 1079-1079.	1.4	0
594	PTPN11 and RAS Gene Mutation Pattern Identifies an Unique Feature of Upregulated RAS Function in Infant ALL.. Blood, 2004, 104, 996-996.	1.4	0

#	Article	IF	Citations
595	Three-Drug Induction and BFM-Type Intensive Consolidation Chemotherapy for Treatment of Standard Risk Childhood Acute Lymphoblastic Leukemia Defined Also by DNA index. The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) Study ALL-9501.. Blood, 2004, 104, 1951-1951.	1.4	0
596	Acute Lymphoblastic Leukemia in Children with Associated Genetic Conditions Other Than Down Syndrome. The AIEOP Experience.. Blood, 2005, 106, 863-863.	1.4	0
597	Acute Differentiated Dendritic Cell Leukemia: A New Form of Pediatric Acute Myeloid Leukemia (AML) with MLL Translocations.. Blood, 2005, 106, 3263-3263.	1.4	0
598	Identification of New Genomic Lesions in Childhood ALL without Known Genetic Aberrations: A Microarray Study of Gene Expression and Genotype Data.. Blood, 2006, 108, 2066-2066.	1.4	0
599	Alterations of Cell Signaling Pathways in Pediatric B-ALL Patients.. Blood, 2006, 108, 4427-4427.	1.4	0
600	Analyses of the Inducible Cyclic Adenosine 3â€²,5â€²-Monophosphate Early Repressor (ICER) and cAMP Response Element Binding Protein (CREB) in HL60 Cells: New Insight Leukemogenesis?.. Blood, 2006, 108, 2251-2251.	1.4	0
601	TEL/AML1 Rearrangement Is Rare in Children with Acute Lymphoblastic Leukemia (ALL) and Down Syndrome (DS). Presenting Features and Treatment Outcome in the Experience of the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP).. Blood, 2007, 110, 848-848.	1.4	0
602	An International Multi-Center Study To Define the Application of Microarray-Based Gene Expression Profiling in the Diagnosis and Sub-Classification of Leukemia (MILE Study): Analysis of Completed Stage I with 2030 Patients Achieved a 95.4% Accuracy.. Blood, 2007, 110, 3169-3169.	1.4	0
603	A New Subtype of Excellent Prognosis Identified by GEP in Childhood BCP-ALL Patients. Blood, 2008, 112, 2513-2513.	1.4	0
604	Integrin Alpha M Chain Expression at Diagnosis Is Inversely Correlated with Cytoreduction Rate and Is Consistently Up-Regulated during Therapy in Acute Lymphoblastic Leukemia (ALL). Blood, 2008, 112, 2526-2526.	1.4	0
605	Gene Expression Profiling Differentiates Childhood Acute Lymphoblastic Leukemia in Down Syndrome Versus Non-Down Syndrome Patients.. Blood, 2008, 112, 1203-1203.	1.4	0
606	Gene Expression Profile Analysis of Pediatric MDS Patients Correlates with FAB Classification and Has Prognostic Relevance. Blood, 2008, 112, 2695-2695.	1.4	0
607	Time to Leukemia (TTL) in NOD/SCID Mice Determines Patient Outcome and Is Characterized by a 5 Genes Signature Associated with Relapse. Blood, 2008, 112, 755-755.	1.4	0
608	Clonal Profile Analysis of Leukemic Progenitors and Diagnosis Blast Cells in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. Blood, 2008, 112, 4879-4879.	1.4	0
609	Prevalence and Prognostic Impact of CEBPA mutations in Children with AML Treated with the AIEOP-LAM 2002/01 Protocol.. Blood, 2009, 114, 2643-2643.	1.4	0
610	Rearrangement of CRLF2 in B-Progenitor and Down Syndrome Associated Acute Lymphoblastic Leukemia.. Blood, 2009, 114, 182-182.	1.4	0
611	Genomic and Transcriptomic Analyses Revealed Differences and Similarities Between T-Lbl and T-ALL .. Blood, 2009, 114, 2943-2943.	1.4	0
612	Xenografts of Pediatric Acute Lymphoblastic Leukemia Retain the Gene Expression Pattern From the Diagnostic Material They Originated From Over Serial Passages.. Blood, 2009, 114, 1629-1629.	1.4	0

#	Article	IF	Citations
613	The Human AF9 Homologue in Zebrafish Is Involved in Primitive Hematopoietic Development.. Blood, 2009, 114, 3653-3653.	1.4	0
614	Detection of CALM-AF10 Fusion Transcript Does Not Predict A Poor Prognosis in Children with T-Lineage Acute Lymphoblastic Leukemia Treated with AIEOP ALL 2000 Protocol and Subsequent Modified 2000 Study (R-2006).. Blood, 2009, 114, 1578-1578.	1.4	0
615	Trisomy of Chromosome 7: a Novel Cytogenetic Abnormality in a Paediatric Case of Mixed Acute Leukemia.. Blood, 2009, 114, 4121-4121.	1.4	0
616	In Infant ALL with t(4;11)/MLL-AF4 Multiple and Phenotypically Distinct CD19+ BM Subsets Initiate Leukemia in NOD/SCID Mice... Blood, 2009, 114, 1432-1432.	1.4	0
617	STAT5 Phosphorylation Status by Flow Cytometry Is a Rapid and Reliable Tool for Diagnosis and Follow-up of Juvenile Myelomonocytic Leukemia. Blood, 2010, 116, 2751-2751.	1.4	0
618	Biological Features and Prognostic Impact of CRLF2 Overexpression In Childhood ALL. Blood, 2010, 116, 271-271.	1.4	0
619	Prognostic Value of Immunophenotype In Infant ALL â€“ Results of the INTERFANT'99 Study. Blood, 2010, 116, 2700-2700.	1.4	0
620	Lack of Protein Kinase C Alpha Is Associated with Poor Prognosis in Pediatric T-Lineage Acute Lymphoblastic Leukemia. Blood, 2011, 118, 744-744.	1.4	0
621	High Risk Acute Lymphoblastic Leukemia with Rapid NOD/SCID Engraftment Is Characterized by High Protein Expression of CYCLIN B, Beta-CATENIN, ANNEXIN I and Decreased PKC Alpha Activation. Blood, 2011, 118, 1457-1457.	1.4	0
622	Discovery of Novel Recurrent Mutations in Childhood Early T-Cell Precursor Acute Lymphoblastic Leukemia by Whole Genome Sequencing - a Report From the St Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project. Blood, 2011, 118, 68-68.	1.4	0
623	BAG1 Overexpression Restrains the Anti-Apoptotic BCL2, MCL1 and HSP70 Proteins in Acute Myeloid Leukemia.. Blood, 2012, 120, 2492-2492.	1.4	0
624	Microvesicles Transcripts As Hallmark and Vector From Leukemic Parental Cells. Blood, 2012, 120, 1459-1459.	1.4	0
625	Hematopoietic Cell Transplantation for Children with High Risk Acute Lymphoblastic Leukemia in First Complete Remission: A Report From the Italian Association of Pediatric Hematology and Oncology (AIEOP) Registry.. Blood, 2012, 120, 3036-3036.	1.4	0
626	Extensive Coagulation Profile in Children with Sickle Cell Disease and Its Role in Cerebral Micro-Vasculopathy. Blood, 2012, 120, 3247-3247.	1.4	0
627	Mosaic Distribution of RAS Pathway Mutated and Non Mutated Cells in Bone Marrow of Juvenile Myelomonocytic Leukemia.. Blood, 2012, 120, 2818-2818.	1.4	0
628	CI-FISH, GEP, and SNPs Correlate Genomic Categories with Risk Stratification in Children with T-ALL.. Blood, 2012, 120, 2485-2485.	1.4	0
629	Favourable Outcome in Infants with Acute Myeloid Leukemia Treated with the AIEOP AML 2002/01 Protocol. Blood, 2012, 120, 3585-3585.	1.4	0
630	NOVEL Recurrent Genetic Aberrations in Pediatric AML: An AIEOP AML-2002 Study Group.. Blood, 2012, 120, 2494-2494.	1.4	0

#	Article	IF	Citations
631	The cAMP Response Element Binding Protein (CREB) Overexpression Induces Myeloid Transformation in Zebrafish. Blood, 2012, 120, 4727-4727.	1.4	0
632	Minimal Residual Disease Monitoring In Acute Lymphoblastic Leukemia Patients Using Immune Receptor Sequencing. Blood, 2013, 122, 1381-1381.	1.4	0
633	Characterization of lincRNA BALIR-6 in MLL rearranged B-lymphoblastic leukemia. Blood, 2013, 122, 3730-3730.	1.4	0
634	Identification Of Low Risk Group In Infants With Acute Lymphoblastic Leukemia By Flow Cytometric Minimal Residual Disease Measurement At Day 15 Of Interfant-99 and Interfant-06 Protocols Treatment. Blood, 2013, 122, 1333-1333.	1.4	0
635	ZNF521 Is a Zinc Finger Protein That Prevents Differentiation Of Human MLL-AF9-Positive Myeloid Leukemic Cells. Blood, 2013, 122, 1255-1255.	1.4	0
636	Expression Level Of A Coagulation Factor Gene, F13A1 Defines Characteristic Subpopulations Of Childhood Acute Lymphoblastic Leukemia. Blood, 2013, 122, 4888-4888.	1.4	0
637	LincRNA Expression Discriminates Cytogenetic Subtypes In B-Lymphoblastic Leukemia and Plays a Functional Role In Leukemia Cell Survival. Blood, 2013, 122, 2570-2570.	1.4	0
638	Refinement of IKZF1 Genomic Status in Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia. Blood, 2014, 124, 3785-3785.	1.4	0
639	Results of an AIEOP (Associazione Italiana di Ematologia e Oncologia Pediatrica) Randomized Clinical Trial in Children with Low- and Intermediate-Risk Relapsed Acute Lymphoblastic Leukemia (ALL). Blood, 2014, 124, 65-65.	1.4	0
640	CREB Controls C/Ebpd to Impair Myeloid Differentiation Process in Acute Myeloid Leukemia. Blood, 2015, 126, 4801-4801.	1.4	0
641	Clinical and Biological Characterization of Children with FLT3ITD Mutated Acute Myeloid Leukemia (AML): A Report from the AIEOP AML-2002 Study Group. Blood, 2015, 126, 3845-3845.	1.4	0
642	Three Dimensional Speckle Tracking Echocardiography (3D-STE) for Early Detection of Subtle Myocardial Deformation Dysfunction in Thalassemic Patients. Blood, 2015, 126, 2158-2158.	1.4	0
643	Characterizing the Function of an RNA Binding Protein, IGF2BP3, in Hematopoiesis. Blood, 2015, 126, 3664-3664.	1.4	0
644	Prognostic Role of Minimal Residual Disease before and after Hematopoietic Stem Cell Transplantation in Childhood Acute Lymphoblastic Leukemia. Blood, 2015, 126, 1413-1413.	1.4	0
645	Could Hemorrhagic and Thrombotic Risk Due to Peg-Asparaginase be Identified By Coagulative Tests Using Fibtem and Antithrombin Levels? A Single Centre Study. Blood, 2015, 126, 2305-2305.	1.4	0
646	Mutational Landscape, Clonal Evolution Patterns and Role of RAS Mutations in Relapsed Acute Lymphoblastic Leukemia. Blood, 2016, 128, 4068-4068.	1.4	0
647	New Therapeutic Opportunities for Pediatric Patients with t(6;11)-Rearranged Acute Myeloid Leukemia. Blood, 2016, 128, 749-749.	1.4	0
648	Evaluation of Minimal Residual Disease As a Surrogate Endpoint for Event Free Survival in Childhood B-Lineage Acute Lymphoblastic Leukemia. Blood, 2016, 128, 759-759.	1.4	0

#	Article	IF	Citations
649	Molecular Characterization of Long Non-Coding RNA CASC15 in Leukemogenesis. Blood, 2016, 128, 5103-5103.	1.4	0
650	Pharmacological Inhibition of Lck is Able to Revert Glucocorticoid Resistance in Pediatric T-ALL. Blood, 2016, 128, 838-838.	1.4	0
651	Elevated Level Expression of MiR-223 Is Associated with Worse Prognosis in Childhood T-Cell Lymphoblastic Lymphoma. Blood, 2016, 128, 1098-1098.	1.4	0
652	Long-Term Outcome of Relapsed Acute T-Lymphoblastic Leukemia (T-ALL) in Children and Adolescents. Blood, 2019, 134, 2580-2580.	1.4	0
653	Prognostic Value of Minimal Residual Disease Measured By Flow Cytometry in Two Cohorts of Infants with Acute Lymphoblastic Leukemia Treated with MLL-Baby and Interfant Protocols in Large Multicenter Networks. Blood, 2019, 134, 2747-2747.	1.4	0
654	Gene symbol: ASL. Disease: Argininosuccinate lyase deficiency. Human Genetics, 2008, 124, 303.	3.8	0